SECURITIES
PURCHASE AGREEMENT

      


      dated as
of October 29, 2009

      


      between

      


      Cascade
Bancorp

      


      and

      


      David
F. Bolger

      


      
        

        

      

      
        
           


        

        
           


          
            

          

        

        
           


        

      


      TABLE
OF CONTENTS

       

      
        
          
            
              
                
                  	 
      	 
      	
                          Page

                        
	 
      	 
      
	
                          Article
      I

                        	
                          2
      

                        
	 
      	 
      
	
                          Purchase;
      Closings

                        	
                          2

                        
	 
      	 
      	 
      
	
                          1.1

                        	
                          Purchase

                        	
                          2
      

                        
	
                          1.2

                        	
                          Closing

                        	
                          2

                        
	 
      	 
	
                          Article
      II

                        	
                          6
      

                        
	 
      	
                          6

                        
	
                          Representations
      and Warranties

                        	 
      
	 
      	 
      	
                          6

                        
	
                          2.1

                        	
                          Disclosure

                        	
                          6

                        
	
                          2.2

                        	
                          Representations
      and Warranties of the Company

                        	
                          7

                        
	
                          2.3

                        	
                          Representations
      and Warranties of the Investor

                        	
                          25

                        
	 
      	 
      
	
                          Article
      III

                        	
                          25

                        
	 
      	 
	
                          Covenants

                        	
                          25

                        
	 
      	 
      	 
      
	
                          3.1

                        	
                          Filings;
      Other Actions

                        	
                          25

                        
	
                          3.2

                        	
                          Expenses

                        	
                          28

                        
	
                          3.3

                        	
                          Access,
      Information and Confidentiality

                        	
                          28

                        
	
                          3.4

                        	
                          Transfer

                        	
                          29

                        
	
                          3.5

                        	
                          Reasonable
      Efforts

                        	
                          29

                        
	
                          3.6

                        	
                          Conduct
      of the Business

                        	
                          29

                        
	
                          3.7

                        	
                          Company
      Forbearances

                        	
                          30

                        
	
                          3.8

                        	
                          Shareholder
      Litigation

                        	
                          31
      

                        
	 
      	 
      
	
                          Article
      IV

                        	
                          32

                        
	 
      	 
      
	
                          Additional
      Agreements

                        	
                          32

                        
	 
      	 
      	 
      
	
                          4.1

                        	
                          No
      Rights Agreement

                        	 
      
	
                          4.2

                        	
                          Governance
      Matters

                        	
                          32
      

                        
	
                          4.3

                        	
                          Legend

                        	
                          32

                        
	
                          4.4

                        	
                          [Reserved]

                        	
                          34

                        
	
                          4.5

                        	
                          Certain
      Transactions

                        	
                          34

                        
	
                          4.6

                        	
                          Indemnity

                        	
                          34

                        
	
                          4.7

                        	
                          Registration
      Rights

                        	
                          36

                        
	
                          4.8

                        	
                          Termination
      of Certain Sections of the Shareholders Agreement

                        	
                          46

                        
	
                          4.9

                        	
                          Market
      Stand-off Provision

                        	
                          47

                        
	
                          4.10

                        	
                          Gross-Up
      Rights

                        	
                          48

                        


                

              

            

          

        

      


      
        
           


        

        
          -i-

          
            

          

        

        
           


        

      

      


      
        
          
            
              	
                      4.11

                    	
                      Anti-Takeover
      Matters

                    	
                      50

                    
	
                      4.12

                    	
                      Additional
      Regulatory Matters

                    	
                      51

                    
	 
      	 
      
	
                      Article
      V

                    	
                      52

                    
	 
      	 
      
	
                      Termination

                    	
                      52

                    
	 
      	 
      	 
      
	
                      5.1

                    	
                      Termination

                    	
                      52

                    
	
                      5.2

                    	
                      Effects
      of Termination

                    	
                      53
      

                    
	 
      	
                       
      

                    
	
                      Article
      VI

                    	
                      53
      

                    
	 
      	 
      
	
                      Miscellaneous

                    	
                      53

                    
	 
      	 
      	 
      
	
                      6.1

                    	
                      Survival

                    	
                      53
      

                    
	
                      6.2

                    	
                      Amendment

                    	
                      53

                    
	
                      6.3

                    	
                      Waivers

                    	
                      53

                    
	
                      6.4

                    	
                      Counterparts
      and Facsimile

                    	
                      53

                    
	
                      6.5

                    	
                      Governing
      Law

                    	
                      53

                    
	
                      6.6

                    	
                      Waiver
      of Jury Trial

                    	
                      54
      

                    
	
                      6.7

                    	
                      Notices

                    	
                      54

                    
	
                      6.8

                    	
                      Entire
      Agreement; Assignment

                    	
                      55
      

                    
	
                      6.9

                    	
                      Other
      Definitions

                    	
                      55

                    
	
                      6.10

                    	
                      Captions

                    	
                      56

                    
	
                      6.11

                    	
                      Severability

                    	
                      57

                    
	
                      6.12

                    	
                      No
      Third-Party Beneficiaries

                    	
                      57

                    
	
                      6.13

                    	
                      Time
      of Essence

                    	
                      57

                    
	
                      6.14

                    	
                      Public
      Announcements

                    	
                      57

                    
	
                      6.15

                    	
                      Specific
      Performance

                    	
                      57

                    
	
                      6.16

                    	
                      No
      Obligation

                    	
                      57

                    


            

          

        

      


      
        
           


        

        
          -ii-

          
            

          

        

        
           


        

      

      


      
        
          
            
              
                
                  	
                          LIST
      OF EXHIBITS

                        	 
      
	 
      	 
      	 
      
	
                          Exhibit A:

                        	
                          Form
      of Opinion of Counsel

                        	 
      
	
                          Exhibit B:

                        	
                          Form
      of Disclosure Letter of Counsel

                        	 
      
	
                          Exhibit C:

                        	
                          Form
      of Officer’s Certificate from the Company

                        	 
      


                

              

            

          

        

      


      
        
           


        

        
          -iii-

          
            

          

        

        
           


        

      


      INDEX
OF DEFINED TERMS

       

      
        
          
            
              
                
                  
                    	
                            Term

                          	 
      	
                            Location
      of

                            Definition

                          
	
                            Additional
      Shares

                          	 
      	
                            1.2(b)

                          
	
                            Affiliate

                          	 
      	
                            6.9(2)

                          
	
                            Agreement

                          	 
      	
                            Preamble

                          
	
                            Articles
      of Incorporation

                          	 
      	
                            2.2(a)

                          
	
                            Beneficially
      Own/Beneficial Owner/Beneficial Ownership

                          	 
      	
                            6.9(9)

                          
	
                            Benefit
      Plan

                          	 
      	
                            2.2(p)(1)

                          
	
                            BHC
      Act

                          	 
      	
                            2.2(a)

                          
	
                            Board
      of Directors

                          	 
      	
                            1.2(c)(1)(xi)

                          
	
                            Bolger
      Transaction Document

                          	 
      	
                            Recitals

                          
	
                            Business
      Combination Exemption Resolution

                          	 
      	
                            4.11(b)

                          
	
                            business
      day

                          	 
      	
                            6.9(7)

                          
	
                            CLAT

                          	 
      	
                            Recitals

                          
	
                            Closing

                          	 
      	
                            1.2(a)

                          
	
                            Closing
      Date

                          	 
      	
                            1.2(a)

                          
	
                            Code

                          	 
      	
                            2.2(p)(2)

                          
	
                            Common
      Stock/Common Shares

                          	 
      	
                            Recitals

                          
	
                            Company

                          	 
      	
                            Preamble

                          
	
                            Company
      10-K

                          	 
      	
                            2.2(c)(1)

                          
	
                            Company
      Bank

                          	 
      	
                            4.2(a)

                          
	
                            Company
      Financial Statements

                          	 
      	
                            2.2(f)

                          
	
                            Company
      Preferred Stock

                          	 
      	
                            2.2(c)(1)

                          
	
                            Company
      Reports

                          	 
      	
                            2.2(g)(1)

                          
	
                            Company
      Restricted Stock

                          	 
      	
                            2.2(c)(1)

                          
	
                            Company
      SEC Filings

                          	 
      	
                            2.2(ee)

                          
	
                            Company
      Significant Agreement

                          	 
      	
                            2.2(k)

                          
	
                            Company
      Stock Option

                          	 
      	
                            2.2(c)(1)

                          
	
                            Company
      Stock Option Plans

                          	 
      	
                            2.2(c)(1)

                          
	
                            Company
      Subsidiary/Company Subsidiaries

                          	 
      	
                            2.2(b)

                          
	
                            control/controlled
      by/under common control with

                          	 
      	
                            6.9(2)

                          
	
                            Covered
      Persons

                          	 
      	
                            4.11(b)

                          
	
                            De
      Minimis Claim

                          	 
      	
                            4.6(e)

                          
	
                            Designated
      Directors

                          	 
      	
                            1.2(c)(1)(xi)

                          
	
                            Disclosure
      Schedule

                          	 
      	
                            2.1(a)

                          
	
                            ERISA

                          	 
      	
                            2.2(p)(1)

                          
	
                            ERISA
      Affiliate

                          	 
      	
                            2.2(p)(2)

                          
	
                            ERISA
      Plan

                          	 
      	
                            2.2(p)(3)

                          
	
                            Exchange
      Act

                          	 
      	
                            2.2(g)(1)

                          
	
                            FDIC

                          	 
      	
                            2.2(b)

                          
	
                            GAAP

                          	 
      	
                            2.2(f)

                          
	
                            Governmental
      Entity

                          	 
      	
                            1.2(c)(1)(i)

                          
	
                            GRAT

                          	 
      	
                            Recitals

                          


                  

                

              

            

          

        

      


      
        
           


        

        
          -iv-

          
            

          

        

        
           


        

      

      


      
        
          
            
              
                
                  
                    
                      	
                              Term

                            	 
      	
                              Location
      of

                              Definition

                            
	
                              herein/hereof/hereunder

                            	 
      	
                              6.9(5)

                            
	
                              Holder

                            	 
      	
                              4.7(k)(1)

                            
	
                              Holders’
      Counsel

                            	 
      	
                              4.7(k)(2)

                            
	
                              including/includes/included/include

                            	 
      	
                              6.9(4)

                            
	
                              Indemnified
      Party

                            	 
      	
                              4.6(c)

                            
	
                              Indemnifying
      Party

                            	 
      	
                              4.6(c)

                            
	
                              Indemnitee

                            	 
      	
                              4.7(g)(1)

                            
	
                              Information

                            	 
      	
                              3.3(b)

                            
	
                              Intellectual
      Property

                            	 
      	
                              2.2(w)

                            
	
                              Investor

                            	 
      	
                              Preamble

                            
	
                              Investor
      Nominee

                            	 
      	
                              4.2(a)

                            
	
                              IRS

                            	 
      	
                              2.2(i)

                            
	
                              IT
      Assets

                            	 
      	
                              2.2(w)

                            
	
                              knowledge
      of the Company/Company’s knowledge

                            	 
      	
                              6.9(10)

                            
	
                              Liens

                            	 
      	
                              2.2(b)

                            
	
                              Losses

                            	 
      	
                              4.6(a)

                            
	
                              Market
      Price

                            	 
      	
                              4.10(a)

                            
	
                              Material
      Adverse Effect

                            	 
      	
                              2.1(b)

                            
	
                              NASDAQ

                            	 
      	
                              1.2(c)(1)(xvi)

                            
	
                              New
      Security

                            	 
      	
                              4.10(a)

                            
	
                              OBCA

                            	 
      	
                              2.2(v)

                            
	
                              Order

                            	 
      	
                              1.2(c)(1)(xiv)

                            
	
                              Other
      Private Placements

                            	 
      	
                              Recitals

                            
	
                              Other
      Securities Purchase Agreements

                            	 
      	
                              Recitals

                            
	
                              Pending
      Underwritten Offering

                            	 
      	
                              4.7(l)

                            
	
                              Pension
      Plan

                            	 
      	
                              2.2(p)(3)

                            
	
                              Per
      Share Purchase Price

                            	 
      	
                              1.2(a)

                            
	
                              Permitted
      Liens

                            	 
      	
                              2.2(h)

                            
	
                              person

                            	 
      	
                              6.9(8)

                            
	
                              Piggyback
      Registration

                            	 
      	
                              4.7(a)(4)

                            
	
                              Pre-Closing
      Period

                            	 
      	
                              3.6

                            
	
                              Previously
      Disclosed

                            	 
      	
                              2.1(c)

                            
	
                              Public
      Offering

                            	 
      	
                              Recitals

                            
	
                              Public
      Offering Price

                            	 
      	
                              1.2(a)

                            
	
                              Purchase
      Price

                            	 
      	
                              1.2(a)

                            
	
                              Purchased
      Shares

                            	 
      	
                              1.2(a)

                            
	
                              Register/registered/registration

                            	 
      	
                              4.7(k)(3)

                            
	
                              Registered
      Intellectual Property

                            	 
      	
                              2.2(w)

                            
	
                              Registrable
      Securities

                            	 
      	
                              4.7(k)(4)

                            
	
                              Registration
      Deadline

                            	 
      	
                              4.7(a)(1)

                            
	
                              Registration
      Expenses

                            	 
      	
                              4.7(k)(5)

                            
	
                              Regulatory
      Agreement

                            	 
      	
                              2.2(y)

                            
	
                              Rule
      144

                            	 
      	
                              4.7(k)(6)

                            


                    

                  

                

              

            

          

        

      


      
        
           


        

        
          -v-

          
            

          

        

        
           


        

      

      


      
        
          
            
              
                
                  
                    	
                            Term

                          	 
      	
                            Location
      of

                            Definition

                          
	
                            Rule
      144A

                          	 
      	
                            4.7(k)(6)

                          
	
                            Rule
      405

                          	 
      	
                            4.7(k)(6)

                          
	
                            Rule
      158

                          	 
      	
                            4.7(k)(6)

                          
	
                            Rule
      159A

                          	 
      	
                            4.7(k)(6)

                          
	
                            Rule
      415

                          	 
      	
                            4.7(k)(6)

                          
	
                            Scheduled
      Black-out Period

                          	 
      	
                            4.7(k)(7)

                          
	
                            SEC

                          	 
      	
                            2.1(c)

                          
	
                            Securities

                          	 
      	
                            1.2(b)

                          
	
                            Securities
      Act

                          	 
      	
                            2.2(g)(1)

                          
	
                            Selling
      Expenses

                          	 
      	
                            4.7(k)(8)

                          
	
                            Shareholders
      Agreement

                          	 
      	
                            4.2(e)

                          
	
                            Shareholder
      Litigation

                          	 
      	
                            3.8

                          
	
                            Shelf
      Registration Statement

                          	 
      	
                            4.7(a)(2)

                          
	
                            Special
      Registration

                          	 
      	
                            4.7(a)(4)

                          
	
                            Stockholder
      Approvals

                          	 
      	
                            2.2(d)(1)

                          
	
                            subsidiary

                          	 
      	
                            6.9(1)

                          
	
                            Takeover
      Law

                          	 
      	
                            2.2(v)

                          
	
                            Tax/Taxes

                          	 
      	
                            2.2(i)

                          
	
                            Tax
      Return

                          	 
      	
                            2.2(i)

                          
	
                            Threshold
      Amount

                          	 
      	
                            4.6(e)

                          
	
                            Trade
      Secrets

                          	 
      	
                            2.2(w)

                          
	
                            Transaction
      Documents

                          	 
      	
                            Recitals

                          
	
                            Trust
      Preferred Securities Repurchase Agreements

                          	 
      	
                            1.2(c)(1)(xiii)

                          
	
                            Two-Forty

                          	 
      	
                            Recitals

                          
	
                            Unlawful
      Gains

                          	 
      	
                            2.2(n)(5)

                          
	
                            Voting
      Debt

                          	
                              

                          	
                            2.2(c)(1)

                          


                  

                

              

            

          

        

      


      
        
           


        

        
          -vi-

          
            

          

        

        
           


        

      


      SECURITIES PURCHASE AGREEMENT,
dated as of October 29, 2009 (this “Agreement”), between Cascade
Bancorp, an Oregon corporation, (the “Company”) and David F.
Bolger, in his individual capacity (the “Investor”).

       

      RECITALS:

       

      A.           The
Investment.  The Company intends to sell to the Investor, and
the Investor intends to purchase from the Company, as an investment in the
Company, the securities as described herein.  The securities to be
purchased at the closing are shares of common stock, no par value, of the
Company (“Common Stock”
or “Common
Shares”).

       

      B.           Additional
Parties.  Solely for the purposes of Sections 3.4, 4.7 and 4.8,
Two-Forty Associates, L.P., a Pennsylvania limited partnership (“Two-Forty”), The David F.
Bolger 2008 Grantor Retained Annuity Trust, a Florida trust (“GRAT”), and The David F.
Bolger 2008 Nongrantor Charitable Lead Annuity Trust, a Florida trust (“CLAT”), shall be deemed
parties to this Agreement.

       

      C.           Additional Private
Placements.  Concurrently with the investment contemplated
herein, the Company has agreed to sell Common Shares in private placements to
other investors (the “Other
Private Placements”) under separate securities purchase agreements (the
“Other Securities Purchase
Agreements”), with the closing of such transactions to occur
simultaneously with the closing of this transaction and the Public Offering as
described herein.

       

      D.           Public
Offering.  Concurrently with the investment contemplated
herein, the Company will sell Common Shares in an underwritten, registered
public offering (the “Public
Offering”), with the closing of such offering to occur simultaneously
with the closing of this transaction as described herein.

       

      E.           Transaction
Documents.  The term “Bolger Transaction Document”
refers to this Agreement, and the term “Transaction Documents” refers
to the Bolger Transaction Document and the Other Securities Purchase
Agreements.

       

      NOW, THEREFORE, in
consideration of the premises, and of the representations, warranties, covenants
and agreements set forth herein, the parties agree as follows:


      
        
           


        

        
           


          
            

          

        

        
           


        

      

       

      ARTICLE
I

       

      Purchase;
Closings

       

      1.1           Purchase.  On
the terms and subject to the conditions set forth herein, the Investor will
purchase from the Company, and the Company will sell to the Investor, a number
of shares of Common Stock as set forth herein.

       

      1.2           Closing.

       

      (a)           Subject
to the satisfaction of the conditions to the closing set forth in
Section 1.2(c), the closing shall take place simultaneously with the
closing of the Public Offering and the Other Private Placements or as shall be
agreed upon in writing by the parties hereto, at the offices of the Company
located at 1100 NW Wall Street, Bend, Oregon 97701 or such other location as
agreed by the parties in writing (the “Closing”).  The
date of the Closing is referred to as the “Closing
Date.”  Subject to the satisfaction of the conditions described
in Section 1.2(c), at the Closing, the Company will deliver to the Investor
one or more certificates representing such number of whole shares of Common
Stock (the “Purchased
Shares”) determined by dividing (i) $25,000,000 (the “Purchase Price”) by the
lesser of (A) $0.87 per share and (B) the net proceeds per share to the Company
in connection with the Public Offering (the “Public Offering Price”) (the
“Per Share Purchase
Price”), against payment by the Investor of $25,000,000 by wire transfer
of immediately available United States funds to a bank account designated by the
Company.

       

      (b)           In
the event that the underwriters in the Public Offering exercise their
over-allotment option to purchase additional shares of Common Stock pursuant to
the underwriting agreement for the Public Offering, then the Company shall
provide written notice to the Investor (which notice shall include the date of
the purchase and the number of shares of Common Stock purchased by the
underwriters) and the Investor shall have the option to purchase, at the Per
Share Purchase Price and on the same terms and conditions as the Purchased
Shares, additional shares of Common Stock (the “Additional Shares” and,
together with the Purchased Shares, the “Securities”) up to the number
of shares of Common Stock, which taken together with the Purchased Shares, would
equal the same percentage of the outstanding shares of Common Stock after the
issuance of the shares of Common Stock pursuant to the over-allotment option as
represented by the Purchased Shares issued pursuant to Section
1.2(a).

       

      (c)           Closing
Conditions.

       

      (1)           The
obligation of the Investor to consummate the Closing is subject to the
fulfillment prior to or contemporaneously with the Closing of each of the
following conditions:


      
        
           


        

        
          -2-

          
            

          

        

        
           


        

      


      (i)           no
provision of any applicable law or regulation and no judgment, injunction, order
or decree shall prohibit the Closing or shall prohibit or restrict Investor or
its Affiliates from owning, voting, or, subject to the receipt of the
Stockholder Approvals (defined below), converting or exercising, any securities
of the Company in accordance with the terms thereof and no lawsuit shall have
been commenced by any court, administrative agency or commission or other
governmental authority or instrumentality, whether federal, state, local or
foreign, or any applicable industry self-regulatory organization (each, a “Governmental Entity”) seeking
to effect any of the foregoing;

       

      (ii)           the
shareholders of Common Shares shall have duly approved the transactions
contemplated hereby, the transactions contemplated by the other Transaction
Documents (to the extent required), and an increase in the number of authorized
Common Shares to 300 million, in each case by the vote required by the Company’s
Articles of Incorporation or the NASDAQ’s listing rules, as applicable, and each
shall have become effective;

       

      (iii)           the
representations and warranties of the Company set forth in this Agreement shall
be true and correct in all respects as of the date hereof and as of the Closing
(except to the extent such representations and warranties are made as of a
specified date, in which case such representations and warranties shall be true
and correct in all respects as of such date);

       

      (iv)           since
the date hereof, there shall not have occurred any circumstance, event, change,
development or effect that, individually or in the aggregate, has had or could
reasonably be expected to have a Material Adverse Effect on the Company or its
principal depository institution subsidiary;

       

      (v)         
  the Company shall have performed all obligations required to be
performed by it at or prior to or contemporaneously with the Closing under this
Agreement;

       

      (vi)           the
Company shall receive proceeds (net of underwriting commissions and discounts)
from the sale of Common Shares of an aggregate amount not less than $150 million
(which includes the Purchase Price), contemporaneously with the Closing, from
the proceeds of the Public Offering, from the Other Private Placements and from
the Investor as contemplated by this Agreement, and all of such proceeds, other
than (A) amounts used to repurchase the trust preferred securities pursuant to
the Trust Preferred Securities Repurchase Agreements and to pay related fees and
expenses (which related fees and expenses shall not exceed $2.7 million); (B)
amounts used to reimburse the Investor and the investors in the Other Private
Placement for their respective fees and expenses pursuant to this Agreement and
the Other Securities Purchase Agreement (which amounts shall not exceed $2.65
million; (C) amounts to pay expenses related to the Public Offering, the Special
Shareholders Meeting and the transactions contemplated by this Agreement and the
Other Purchase Agreements (which amounts shall not exceed $1.5 million); and (D)
up to $1 million which will remain at the Company for working capital purposes,
shall be contributed as capital to the Company’s principal depository
institution subsidiary;

       

      (vii)           the
Company shall have issued new Common Stock certificates pursuant to Section
3.4(a);


      
        
           


        

        
          -3-

          
            

          

        

        
           


        

      

       

      (viii)          the
Company shall have reimbursed the Investor for out-of-pocket fees and expenses
incurred by the Investor in connection with the transaction contemplated hereby
and with any proposed financing thereof, including, but not limited to, fees and
disbursements of legal counsel, accounting and financial advisors, credit review
and investment banking advisors, up to $1,250,000 in the aggregate;

       

      (ix)         
   Davis Wright Tremaine LLP, counsel for the Company, shall have
delivered to the Investor their written opinion, dated the Closing Date, in the
form set forth in Exhibit A hereto, in
form and substance satisfactory to the Investor;

       

      (x)    
        Davis Wright Tremaine LLP, counsel
for the Company, shall have delivered to the Investor their written opinion and
disclosure letter delivered in connection with the Public Offering, dated the
Closing Date, in the form set forth in Exhibit B hereto, in
form and substance satisfactory to the Investor;

       

      (xi)     
      Delap LLP, in their capacity as the
Company’s independent public accountants, shall have delivered to the Investor
and to the Investor’s designated directors (the “Designated Directors”) on the
board of directors of the Company (the “Board of Directors”) a
comfort letter that is addressed to them that is the same as the comfort letter
delivered to the underwriters in connection with the Public Offering, in form
and substance satisfactory to the Investor;

       

      (xii)           the
Company shall have delivered to the Investor a duly executed Officer’s
Certificate in the form set forth in Exhibit C
hereto;

       

      (xiii)          by
November 16, 2009, the Company shall have entered into agreements that are not
subject to any conditions in the control of the holder or termination rights by
such holder to repurchase and cancel at least $66.5 million aggregate
liquidation amount of the outstanding trust preferred securities by issuer
trusts originated by the Company at a discount of not less than 80% of such
aggregate liquidation amount (the “Trust Preferred Securities
Repurchase Agreements”), and, as of the Closing, either (i) the
transactions contemplated by the Repurchase Agreements shall have been
consummated or (ii) the Trust Preferred Securities Repurchase Agreements shall
be in full force and effect and shall not have been modified or amended in any
material respect;

       

      (xiv)          the
Company and its Subsidiaries shall be in compliance in all material respects
with the policies and procedures adopted by them and disclosed to the Investor
in the Three Year Financial Plan dated October 13, 2009, and none of such
policies and procedures shall have been revoked or modified in any respect that
would make it materially less likely that the Company and its Subsidiaries will
be able to comply with a cease-and-desist order dated August 27, 2009 against
the Company Bank issued by the FDIC and the Oregon Division of Finance and
Corporate Securities (or any other enforcement orders in effect at the date
hereof) (the “Order”);


      
        
           


        

        
          -4-

          
            

          

        

        
           


        

      

       

      (xv)           as
of the close of business on the second business day immediately preceding the
Closing, the Company’s (A) classified assets on its balance sheet shall not be
more than 10% higher than the amount set forth as of September 30, 2009, (B)
non-performing assets on its balance sheet shall not be more than 17.5% higher
than the amount set forth as of September 30, 2009 and (C) the Company’s net
loss, exclusive of tax adjustments or tax expense, for the period October 1,
2009 to the second business day prior to the Closing Date, shall not exceed $25
million;

       

      (xvi)          the
Company shall have caused the shares of Common Stock issuable at Closing and the
shares of Common Stock to be issued in the Other Private Placements and the
Public Offering to be approved for listing on the National Association of
Securities Dealers Automated Quotation System (“NASDAQ”), subject to official
notice of issuance;

       

      (xvii)          the
Company and the Investor shall have obtained the approvals and authorizations
of, filings and registrations with, and notifications to, and, to the extent
required by applicable law or regulation, consents, approvals, or exemptions
from bank regulatory authorities, for the transactions contemplated by the
Transaction Documents;

       

      (xviii)        except
as Previously Disclosed (as defined below), no enforcement action shall have
been threatened or issued by any governmental agency with regulatory authority
over the Company and its subsidiaries.

       

      At
Closing, the Company shall deliver a certificate of the Chief Executive Officer
or the Chief Financial Officer certifying compliance with each of the above
conditions and upon the request of the Investor, shall provide sufficient detail
that the Investor may verify compliance.

       

      (2)           The
obligation of the Company to consummate the Closing is subject to the
fulfillment prior to the Closing of each of the following
conditions:

       

      (i)           the
representations and warranties of the Investor set forth in Section 2.3(a)
of this Agreement shall be true and correct in all respects as of the date
hereof and as of the Closing (except to the extent such representations and
warranties are made as of a specified date, in which case such representations
and warranties shall be true and correct in all respects as of such
date);

       

      (ii)           the
Company shall receive proceeds from the sale of Common Shares (net of
underwriting commissions and discounts) of an aggregate amount not less than
$150 million (which includes the Purchase Price), contemporaneously with the
Closing, from the proceeds of the Public Offering, from the Other Private
Placements and from the Investor as contemplated by this
Agreement;


      
        
           


        

        
          -5-

          
            

          

        

        
           


        

      

       

      (iii)           the
Company and the Investor shall have obtained the approvals and authorizations
of, filings and registrations with, and notifications to, and, to the extent
required by applicable law or regulation, consents, approvals, or exemptions
from bank regulatory authorities, for the transactions contemplated by the
Transaction Documents; and

       

      (iv)           the
Investor shall have performed all obligations required to be performed by it at
or prior to the Closing under this Agreement.

       

      ARTICLE
II

       

      Representations
and Warranties

       

      2.1           Disclosure.

       

      (a)           On
or prior to the date of this Agreement, the Company delivered to the Investor a
schedule (“Disclosure
Schedule”) setting forth, among other things, items the disclosure of
which is necessary or appropriate either in response to an express disclosure
requirement contained in a provision hereof or as an exception to one or more
representations or warranties contained in Section 2.2 or to one or more of its covenants contained in
Article III; provided,
however, that
notwithstanding anything in this Agreement to the contrary, the mere inclusion
of an item in such schedule shall not be deemed an admission that such item
represents a material exception or material fact, event, or circumstance or that
such item has had or would reasonably be expected to have a Material Adverse
Effect on the Company.

       

      (b)           “Material Adverse Effect”
means, with respect to the Investor, only clause (2) that follows, or, with
respect to the Company, both clauses (1) and (2) that follow, any
circumstance, event, change, development or effect that, individually or in the
aggregate (1) is or would reasonably be expected to be material and adverse
to the financial position, results of operations, business, management or
condition (financial or otherwise) of the Company and its subsidiaries taken as
a whole, or (2) would materially impair the ability of either the Investor
or the Company, respectively, to perform its respective obligations under this
Agreement or otherwise materially threaten or materially impede the consummation
of the transactions contemplated by this Agreement; provided, however, that in determining
whether a Material Adverse Effect has occurred, there shall be excluded any
effect to the extent resulting from the following: (A) changes, after the date
hereof, in generally accepted accounting principles or regulatory accounting
principles generally applicable to banks, savings associations or their holding
companies, (B) actions or omissions of the Company expressly required by the
terms of this Agreement or taken with the prior written consent of each
Investor, (C) changes, after the date hereof, in the market price or trading
volumes of the Common Stock or the Company’s other securities (but not the
underlying causes of such changes), (D) changes in global or national political
conditions, including the outbreak or escalation of war or acts of terrorism,
and (E) the public disclosure of this Agreement or the transactions contemplated
hereby; except, with respect to clauses (A), and (D), to the extent that the
effects of such changes have a disproportionate effect on the Company and the
Company Subsidiaries, taken as a whole, relative to other banks, savings
associations and their holding companies generally, and with respect to clause
(E), to the extent that such public disclosure results in additional
restrictions or sanctions against the Company or the Bank by a regulatory
authority.


      
        
           


        

        
          -6-

          
            

          

        

        
           


        

      

       

      (c)           “Previously Disclosed” with
regard to the Company means (1) information set forth on its Disclosure Schedule
corresponding to the provision of this Agreement to which such information
relates; provided that
information which is reasonably apparent on its face that it relates to another
provision of this Agreement, shall also be deemed to be Previously Disclosed
with respect to such other provision and (2) includes information publicly
disclosed by the Company in the Company Reports filed by it with or furnished to
the U.S. Securities and Exchange Commission (the “SEC”) or in the Registration
Statement on Form S-1 (Reg. No. 333-162377), including amendments thereto filed
prior to the date hereof, and publicly available prior to the date of this
Agreement (excluding any risk factor disclosures contained in such documents
under the heading “Risk Factors,” any disclosure of risks included in any
“forward-looking statements” or any other disclaimer that are non-specific and
predictive or forward-looking in nature and any exhibits thereto and documents
incorporated by reference therein).

       

      2.2           Representations and
Warranties of the Company.  Except
as Previously Disclosed, the Company represents and warrants as of the date of
this Agreement and as of the Closing (except to the extent made only as of a
specified date, in which case as of such date) to the Investor
that:

       

      (a)           Organization and
Authority.  The Company is a corporation duly organized and
validly existing under the laws of the State of Oregon, is duly qualified to do
business and is in good standing in all jurisdictions where its ownership or
leasing of property or the conduct of its business requires it to be so
qualified and failure to be so qualified would have a Material Adverse Effect on
the Company and has corporate power and authority to own its properties and
assets and to carry on its business as it is now being conducted.  The
Company is duly registered as a bank holding company under the Bank Holding
Company Act of 1956, as amended, or any successor statute (the “BHC Act”).  The
Company has furnished or made available to the Investor, prior to the date
hereof, true, correct and complete copies of the Company’s Articles of
Incorporation, as amended on April 21, 1997 (the “Articles of Incorporation”)
and bylaws as amended through the date of this Agreement.


      (b)           Company’s
Subsidiaries.  The Company has Previously Disclosed a true,
complete and correct list of all of its subsidiaries as of the date of this
Agreement (individually, a “Company Subsidiary” and,
collectively, the “Company
Subsidiaries”), all shares of the outstanding capital stock of each of
which are owned directly or indirectly by the Company.  No equity
security of any Company Subsidiary is or may be required to be issued by reason
of any option, warrant, scrip, preemptive right, right to subscribe to, gross-up
right, call or commitment of any character whatsoever relating to, or security
or right convertible into, shares of any capital stock of such Company
Subsidiary, and there are no contracts, commitments, understandings or
arrangements by which any Company Subsidiary is bound to issue additional shares
of its capital stock, or any option, warrant or right to purchase or acquire any
additional shares of its capital stock.  All of such shares so owned
by the Company are duly authorized and validly issued, fully paid and
nonassessable and are owned by it free and clear of any lien, adverse right or
claim, charge, option, pledge, covenant, title defect, security interest or
other encumbrances of any kind (“Liens”) with respect
thereto.  Each Company Subsidiary is an entity duly organized, validly
existing, duly qualified to do business and in good standing under the laws of
its jurisdiction of organization, and has corporate or other appropriate
organizational power and authority to own or lease its properties and assets and
to carry on its business as it is now being conducted, except as would not
reasonably be expected to have a Material Adverse Effect on the
Company.  Except in respect of the Company Subsidiaries, the Company
does not own beneficially, directly or indirectly, more than 5% of any class of
equity securities or similar interests of any corporation, bank, business trust,
association or similar organization, and is not, directly or indirectly, a
partner in any partnership or party to any joint venture.  The
Company’s principal depository institution subsidiary is duly organized and
validly existing as an Oregon state-chartered commercial bank and its deposit
accounts are insured by the Federal Deposit Insurance Corporation (the “FDIC”) to the fullest extent
permitted by the Federal Deposit Insurance Act and the rules and regulations of
the FDIC thereunder, and all premiums and assessments required to be paid in
connection therewith have been paid when due.  The Company has
furnished or made available to the Investor, prior to the date hereof, true,
correct and complete copies of the charter and bylaws of the Company’s principal
depository institution subsidiary as amended through the date of this
Agreement.

       

      
        
          
          

        

        
          -7-

          
            

          

        

        
          
          

        

      

       

      (c)           Capitalization.


      (1)           As
of the date hereof, the authorized capital stock of the Company consists of
45,000,000 shares of Common Stock and 5,000,000 shares of preferred stock, no
par value (the “Company
Preferred Stock”).  As of the date hereof, there are 28,151,480
shares of Common Stock outstanding and no shares of Company Preferred Stock
outstanding.  From the date of this Agreement through the Closing
Date, except in connection with the Transaction Documents, the Other Private
Placements, the Public Offering and the transactions contemplated hereby
(including any repurchase of Trust Preferred Securities) and thereby, the
Company shall not have (i) issued or authorized the issuance of any shares
of Common Stock or Company Preferred Stock, or any securities convertible into
or exchangeable or exercisable for shares of Common Stock or Company Preferred
Stock (other than shares issued upon the exercise of Company Stock Options),
(ii) reserved for issuance any shares of Common Stock or Company Preferred
Stock or (iii) repurchased or redeemed, or authorized the repurchase or
redemption of, any shares of Common Stock or Company Preferred
Stock.  As of the date hereof, there are (i) outstanding stock
options issued under the Company’s 1994 Incentive Stock Option Plan, as amended
or supplemented as filed as exhibits 10.1 and 10.2 to the Company’s Annual
Report on Form 10-K for the year ended December 31, 2008 (the “Company 10-K”), Deferred
Compensation Plans as filed as exhibit 10.3 to the Company 10-K, 2002 Equity
Incentive Plan, as filed as exhibit 10.4 to the Company 10-K (together, the
“Company Stock Option
Plans”) to purchase an aggregate of 1,004,914 shares of the Common Stock
(each, a “Company Stock
Option”), (ii) an aggregate of 143,545 shares of restricted stock
(“Company Restricted
Stock”) outstanding under the Company Stock Option Plans and (iii)
1,338,921 shares of the Common Stock reserved for issuance under the Company
Stock Option Plans.  Other than in respect of awards outstanding under
or pursuant to the Company Stock Option Plans, no shares of Common Stock or
Company Preferred Stock are reserved for issuance.  All of the issued
and outstanding shares of Common Stock have been duly authorized and validly
issued and are fully paid, nonassessable and free of preemptive rights, with no
personal liability attaching to the ownership thereof.  Each Company
Stock Option (i) was granted in compliance with all applicable laws and all of
the terms and conditions of the Company Stock Option Plans pursuant to which it
was issued, (ii) has an exercise price per share of Common Stock equal to or
greater than the fair market value of a share of Common Stock on the date of
such grant and (iii) has a grant date identical to the date on which the Board
of Directors or compensation committee of the Board of Directors actually
awarded such Company Stock Option.  Neither the Company nor any of its
officers, directors, or employees is a party to any right of first refusal,
right of first offer, proxy, voting agreement, voting trust, registration rights
agreement, or shareholders agreement with respect to the sale or voting of any
securities of the Company.  No bonds, debentures, notes or other
indebtedness having the right to vote on any matters on which the stockholders
of the Company may vote (“Voting Debt”) are issued and
outstanding.  Except as set forth elsewhere in this
Section 2.2(c), the Company does not have and is not bound by any
outstanding subscriptions, options, warrants, calls, repurchase rights,
commitments, or agreements of any character calling for the purchase or issuance
of, or securities or rights convertible into or exchangeable or exercisable for,
any shares of Common Stock or Company Preferred Stock or any other equity
securities of the Company or Voting Debt or any securities representing the
right to purchase or otherwise receive any shares of capital stock of the
Company (including any rights plan or agreement).  The Company has
Previously Disclosed all shares of Company capital stock that have been
purchased, redeemed or otherwise acquired, directly or indirectly, by the
Company or any Company Subsidiary since December 31, 2008 and all dividends or
other distributions that have been declared, set aside, made or paid to the
stockholders of the Company since that date.

       

      
        
          
          

        

        
          -8-

          
            

          

        

        
          
          

        

      

       

      (2)           Section 2.2(c)(2)
of the Company’s Disclosure Schedule sets forth the following information with
respect to each Company Stock Option and share of Company Restricted Stock,
which is true and correct as of the date of this Agreement: (i) the name of each
holder of Company Stock Options and Company Restricted Stock and (ii) the number
of shares of Common Stock subject to such Company Stock Option and the number of
shares of Company Restricted Stock, and, as applicable, the grant date, exercise
price, number of shares vested or not otherwise subject to restrictions, vesting
schedule and the Company Stock Option Plan under which such Company Stock
Options or shares of Company Restricted Stock were granted.

       

      
        
          
          

        

        
          -9-

          
            

          

        

        
          
          

        

      

       

      (d)           Authorization.

       

      (1)           The
Company has the corporate power and authority to enter into or issue this
Agreement and the other Transaction Documents and, subject to obtaining the
Stockholder Approvals (defined below) to carry out its obligations hereunder and
thereunder.  The execution, delivery and performance of this Agreement
and the other Transaction Documents by the Company and the consummation of the
transactions contemplated hereby and thereby, including the issuance of Common
Stock in accordance with the terms of this Agreement and the increase in the
authorized shares of the Company, have been duly authorized by the affirmative
vote of at least a majority of the directors on the Board of
Directors.  This Agreement and the other Transaction Documents have
been duly and validly executed and delivered by the Company and, assuming due
authorization, execution and delivery of this Agreement by the Investor, are
valid and binding obligations of the Company enforceable against the Company in
accordance with their respective terms, except as such enforceability may be
limited by the failure to obtain the Stockholder Approvals, by bankruptcy,
insolvency, moratorium, reorganizations, fraudulent transfer or similar laws
relating to or affecting creditors generally or by general equitable principles
(whether applied in equity or at law).  No other corporate proceedings
are necessary for the execution and delivery by the Company of this Agreement
and the other Transaction Documents, the performance by the Company of its
obligations hereunder and thereunder or the consummation by the Company of the
transactions contemplated hereby and thereby, subject to receipt of the
Stockholder Approvals.  The only vote of the stockholders of the
Company required to approve (i) the amendment of the Articles of Incorporation
to increase the number of authorized shares of Common Stock to at least such
number as shall be sufficient to permit the issuance of Common Stock
contemplated in this Agreement, the issuance of Common Stock in connection with
the Other Private Placements and the issuance of Common Stock in connection with
the Public Offering is that more votes are cast for such proposal than against
the proposal and (ii) the issuance of such authorized shares of Common Stock for
purposes of rule 5635 of NASDAQ’s listing rules is a majority of the votes cast
on such proposal (such stockholder approval to amend the Articles of
Incorporation and to issue the Common Stock, the “Stockholder
Approvals”).  The Board of Directors has resolved that the
transactions contemplated hereby, by the Other Private Placements and by the
Public Offering are in the best interests of stockholders of the Company and has
determined unanimously to recommend to the stockholders the approval of the
actions with respect to the Stockholder Approvals.

       

      (2)           Neither
the execution, delivery and performance by the Company of this Agreement, the
Common Stock and the Other Transaction Documents, nor the consummation of the
transactions contemplated hereby and thereby, nor the consummation of the
transactions contemplated by any of the Other Private Placements or the Public
Offering, nor compliance by the Company with any of the provisions of any of the
foregoing, will (i) violate, conflict with, or result in a breach of any
provision of, or constitute a default (or an event which, with notice or lapse
of time or both, would constitute a default) under, or result in the termination
of, or accelerate the performance required by, or result in a right of
termination or acceleration of, or result in the creation of, any Lien, upon any
of the properties or assets of the Company or any Company Subsidiary under any
of the terms, conditions or provisions of (A) subject to the receipt of the
Stockholder Approvals, its Articles of Incorporation or bylaws (or similar
governing documents) or (B) any note, bond, mortgage, indenture, deed of
trust, license, lease, agreement or other instrument or obligation to which the
Company or any Company Subsidiary is a party or by which it may be bound, or to
which the Company or any Company Subsidiary or any of the properties or assets
of the Company or any Company Subsidiary may be subject, or (ii) subject to
compliance with the statutes and regulations referred to in the next paragraph,
violate any ordinance, permit, concession, grant, franchise, law, statute, rule
or regulation or any judgment, ruling, order, writ, injunction or decree
applicable to the Company or any Company Subsidiary or any of their respective
properties, except in the case of clauses (i)(B) and (ii) for such violations,
conflicts and breaches that are not material.


      
        
           


        

        
          -10-

          
            

          

        

        
           


        

      

       

      (3)           Other
than the securities or blue sky laws of the various states and filings, notices,
approvals or clearances required under federal or state banking laws, no notice
to, registration, declaration or filing with, exemption or review by, or
authorization, order, consent or approval of, any Governmental Entity, or
expiration or termination of any statutory waiting period, is necessary for the
consummation by the Company of the transactions contemplated by this Agreement
or the other Transaction Documents.

       

      (e)           Knowledge as to
Conditions. As of the date of this Agreement, the Company knows of no
reason why any regulatory approvals and, to the extent necessary, any other
approvals, authorizations, filings, registrations, and notices required or
otherwise a condition to the consummation of the transactions contemplated by
the Transaction Documents or the Public Offering will not be
obtained.

       

      (f)           Financial
Statements.  The consolidated balance sheets of the Company as
of December 31, 2008 and 2007 and related consolidated statements of income,
stockholders’ equity and cash flows for the three years ended December 31,
2008, together with the notes thereto, certified by Symonds, Evans &
Company, P.C. and included in the Company 10-K, as filed with the SEC, and the
unaudited consolidated balance sheets of the Company as of September 30, 2009,
June 30, 2009 and March 31, 2009 and related consolidated statements of income,
stockholders’ equity and cash flows for the periods then ended, included in the
Company’s Quarterly Reports on Form 10-Q for the periods ended September 30,
2009, June 30, 2009 and March 31, 2009 (collectively, the “Company Financial
Statements”), (1) have been prepared from, and are in accordance with,
the books and records of the Company and the Company Subsidiaries, (2) complied,
as of their respective date of filing with the SEC, in all material respects
with applicable accounting requirements and with the published rules and
regulations of the SEC with respect thereto, (3) have been prepared in
accordance with U.S. generally accepted accounting principles (“GAAP”) applied on a
consistent basis and (4) present fairly in all material respects the
consolidated financial position of the Company and the Company Subsidiaries at
the dates set forth therein and the consolidated results of operations, changes
in stockholders’ equity and cash flows of the Company and the Company
Subsidiaries for the periods stated therein (subject to the absence of notes and
year-end audit adjustments in the case of interim unaudited
statements).

       

      
        
          
          

        

        
          -11-

          
            

          

        

        
          
          

        

      

       

      (g)           Reports.


      (1)           Since
December 31, 2006, the Company and each Company Subsidiary have filed all
reports, registrations, documents, filings, statements and submissions together
with any required amendments thereto, that it was required to file with any
Governmental Entity (the foregoing, collectively, the “Company Reports”) and have
paid all fees and assessments due and payable in connection
therewith.  As of their respective filing dates, the Company Reports
complied in all material respects with all statutes and applicable rules and
regulations of the applicable Governmental Entities, as the case may
be.  As of the date of this Agreement, there are no outstanding
comments from the SEC or any other Governmental Entity with respect to any
Company Report.  The Company Reports, including the documents
incorporated by reference in each of them, each contained all of the information
required to be included in it and, when it was filed and as of the date of each
such Company Report filed with or furnished to the SEC, such Company Report did
not, as of its date or if amended prior to the date of this Agreement, as of the
date of such amendment, contain an untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements made in it
not misleading and complied as to form in all material respects with the
applicable requirements of the Securities Act of 1933, as amended, or any
successor statute (the “Securities Act”), and the
Securities Exchange Act of 1934, as amended, or any successor statute (the
“Exchange
Act”).  No executive officer of the Company has failed in any
respect to make the certifications required of him or her under Section 302
or 906 of the Sarbanes-Oxley Act of 2002.  There are no facts or
circumstances that would prevent its chief executive officer and chief financial
officer from giving the certifications and attestations required pursuant to
Rules 13a-14 and 15d-14 under the Exchange Act, without qualification, when next
due.

       

      (2)           The
records, systems, controls, data and information of the Company and the Company
Subsidiaries are recorded, stored, maintained and operated under means
(including any electronic, mechanical or photographic process, whether
computerized or not) that are under the exclusive ownership and direct control
of the Company or the Company Subsidiaries or accountants (including all means
of access thereto and therefrom).  The Company (A) has
implemented and maintains disclosure controls and procedures (as defined in Rule
13a-15(e) of the Exchange Act) to ensure that material information relating to
the Company, including its consolidated subsidiaries, is made known to the chief
executive officer and the chief financial officer of the Company by others
within those entities, and (B) has disclosed, based on its most recent
evaluation prior to the date of this Agreement, to the Company’s outside
auditors and the audit committee of the Board of Directors (x) any
significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting (as defined in Rule 13a-15(f) of the
Exchange Act) that are reasonably likely to adversely affect the Company’s
ability to record, process, summarize, and report financial information, and
(y) any fraud, whether or not material, that involves management or other
employees who have a significant role in the Company’s internal controls over
financial reporting.  The Company has no knowledge of any reason that
its outside auditors and its chief executive officer and chief financial officer
will not be able to give the certifications and attestations required pursuant
to the rules and regulations adopted pursuant to Section 404 of the
Sarbanes-Oxley Act of 2002, without qualification, when next
due.  Since December 31, 2006, (i) neither the Company nor any Company
Subsidiary nor, to the knowledge of the Company, any director, officer,
employee, auditor, accountant or representative of the Company or any Company
Subsidiary has received or otherwise had or obtained knowledge of any material
complaint, allegation, assertion or claim, whether written or oral, regarding
the accounting or auditing practices, procedures, methodologies or methods of
the Company or any Company Subsidiary or their respective internal accounting
controls, including any material complaint, allegation, assertion or claim that
the Company or any Company Subsidiary has engaged in questionable accounting or
auditing practices, and (ii) no attorney representing the Company or any Company
Subsidiary, whether or not employed by the Company or any Company Subsidiary,
has reported evidence of a violation of securities laws, breach of fiduciary
duty or similar violation by the Company or any of its officers, directors,
employees or agents to the Board of Directors or any committee thereof or to any
director or officer of the Company.


      
        
           


        

        
          -12-

          
            

          

        

        
           


        

      

       

      (h)           Properties and
Leases.  Except for any Permitted Liens, the Company and each
Company Subsidiary have good title free and clear of any Liens to all the real
and personal property reflected in the Company’s consolidated balance sheet as
of December 31, 2008 included in the Company 10-K for the period then ended, and
all real and personal property acquired since such date, except such real and
personal property as has been disposed of in the ordinary course of
business.  For purposes of this Agreement, “Permitted Liens” means (i)
Liens for taxes and other governmental charges and assessments arising in the
ordinary course which are not yet due and payable, (ii) Liens of landlords and
Liens of carriers, warehousemen, mechanics and materialmen and other like Liens
arising in the ordinary course of business for sums not yet due and payable, and
(iii) other Liens or imperfections on property which are not material in amount
or do not materially detract from the value of or materially impair the existing
use of the property affected by such Lien or imperfection.  Except as
would not be expected to have a Material Adverse Effect, all leases of real
property and all other leases pursuant to which the Company or such Company
Subsidiary, as lessee, leases real or personal property are valid and effective
in accordance with their respective terms and there is not, under any such
lease, any existing default by the Company or such Company Subsidiary or any
event which, with notice or lapse of time or both, would constitute such a
default.

       

      (i)           Taxes.


      (1)           Each
of the Company and the Company Subsidiaries has filed all federal, state,
county, local and foreign material Tax Returns required to be filed by it and
paid all Taxes owed by it and no Taxes owed by it or assessments received by it
are delinquent.  The federal income Tax Returns of the Company and the
Company Subsidiaries for the fiscal year ended December 31, 2006, and for all
fiscal years prior thereto, are for the purposes of routine audit by the
Internal Revenue Service (the “IRS”) closed because of the
statute of limitations, and no claims for additional Taxes for such fiscal years
are pending.  Neither the Company nor any Company Subsidiary has
waived any statute of limitations with respect to Taxes or agreed to any
extension of time with respect to a Tax assessment or deficiency, in each case
that is still in effect, or has pending a request for any such extension or
waiver.  Neither the Company nor any Company Subsidiary is a party to
any pending action or proceeding, nor to the Company’s knowledge, is any such
action or proceeding threatened by any Governmental Entity, for the assessment
or collection of Taxes, interest, penalties, assessments or deficiencies and no
material deficiencies have been proposed by any federal, state, local or foreign
taxing authority in connection with an audit or examination of the Tax Returns,
business or properties of the Company or any Company Subsidiary which has not
been settled, resolved and fully satisfied, or for which reserves adequate in
accordance with GAAP have not been provided.  Each of the Company and
the Company Subsidiaries has withheld and paid all Taxes that it is required to
withhold from amounts owing to employees, creditors or other third
parties.  Neither the Company nor any Company Subsidiary is a party
to, is bound by or has any obligation under, any material Tax sharing or
material Tax indemnity agreement or similar contract or arrangement other than
any contract or agreement between or among the Company and any Company
Subsidiary.  Neither the Company nor any Company Subsidiary has
participated in any “reportable transaction” within the meaning of Treasury
Regulations Section 1.6011-4, or any other transaction requiring disclosure
under analogous provisions of state, local or foreign law.  Neither
the Company nor any Company Subsidiary has liability for the Taxes of any person
other than the Company or any Company Subsidiary under Treasury Regulations
Section 1.1502-6 (or any similar provision of state, local or foreign
law).  The Company has not been a “distributing corporation” or a
“controlled corporation” in any distribution in which the parties to such
distribution treated the distribution as one to which Section 355 of the
Code is applicable.  The Company has not been a United
States real property holding corporation within the meaning of Section 897 of
the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of
the Code.  For the purpose of this Agreement, the term “Tax” (including, with
correlative meaning, the term “Taxes”) shall mean any and
all domestic or foreign, federal, state, local or other taxes of any kind
(together with any and all interest, penalties, additions to tax and additional
amounts imposed with respect thereto) imposed by any Governmental Entity,
including taxes on or with respect to income, franchises, windfall or other
profits, gross receipts, property, sales, use, capital stock, payroll,
employment, unemployment, social security, workers’ compensation or net worth,
and taxes in the nature of excise, withholding, ad valorem or value added or
similar taxes, and the term “Tax Return” means any return,
report, information return or other document (including any related or
supporting information, and attachments and exhibits) required to be filed with
respect to Taxes, including, without limitation, all information returns
relating to Taxes of third parties, any claims for refunds of Taxes and any
amendment or supplements to any of the foregoing.


      
        
           


        

        
          -13-

          
            

          

        

        
           


        

      

    

    (2)           To
the knowledge of the Company, the deferred tax asset on the Company’s balance
sheet as of September 30, 2009 (as referenced in Note 8 thereto) does not
require a material valuation reserve at September 30, 2009.

     

    (3)           Under
the current tax planning strategy as disclosed to the Investor, the Company
expects that it will receive the income tax refund from the calendar year 2007
included as a refundable income taxes receivable discussed in the notes to the
Company’s financial statements for the period ended September 30,
2009.

     

    (j)           Absence of Certain
Changes.  Since December 31, 2008, the Company has not, and no
Company Subsidiary has, made or declared any distribution or dividend in cash or
in kind to its stockholders or issued or repurchased any shares of its capital
stock or other equity interests.  Since December 31, 2008, the
business and operations of the Company and the Company Subsidiaries have been
conducted in the ordinary course of business consistent with past practice, and
there has not been:

     

    (1)           Except
as Previously Disclosed, any circumstance, occurrence, or development which,
individually or in the aggregate with other circumstances, occurrences, or
developments, has had or is reasonably likely to have a Material Adverse Effect
on the Company;

     

    (2)           any
material damage, destruction, or other casualty loss with respect to any
material asset or property owned, leased, or otherwise used by the Company or
any Company Subsidiary, whether or not covered by insurance; or


    
      
         


      

      
        -14-

        
          

        

      

      
         


      

    


    (3)           any
change in any method of accounting or accounting policies by the
Company.

     

    (k)           Commitments and
Contracts.  The Company has Previously Disclosed or provided to
the Investor or his representatives, prior to the date hereof, true, correct,
and complete copies of each of the following to which the Company or any Company
Subsidiary is a party or subject (whether written or oral, express or implied)
(each, a “Company Significant
Agreement”):

     

    (1)           any
labor contract or agreement with any labor union;

     

    (2)           any
contract or agreement which grants any person a right of first refusal, right of
first offer or similar right with respect to any material properties, assets or
businesses of the Company or the Company Subsidiaries;

     

    (3)           any
contract containing covenants that limit the ability of the Company or any
Company Subsidiary to compete in any line of business or with any person or
which involve any restriction of the geographical area in which, or method by
which or with whom, the Company or any Company Subsidiary may carry on its
business (other than as may be required by law or applicable regulatory
authorities); and any contract that could require the disposition of any
material assets or line of business of the Company or any Company
Subsidiary;

     

    (4)           any
joint venture, partnership, strategic alliance, or other similar contract
(including any franchising agreement, but in any event, excluding introducing
broker agreements); and any contract relating to the acquisition or disposition
of any material business or material assets (whether by merger, sale of stock or
assets, or otherwise), which acquisition or disposition is not yet complete or
where such contract contains continuing material obligations or contains
continuing indemnity obligations of the Company or any of the Company
Subsidiaries;

     

    (5)           any
real property lease and any other lease with annual rental payments aggregating
$1,000,000 or more;

     

    (6)           other
than with respect to loans, any contract providing for, or reasonably likely to
result in, the receipt or expenditure of more than $1,000,000 on an annual
basis, including the payment or receipt of royalties or other amounts calculated
based upon revenues or income;

     

    (7)           any
contract or arrangement under which the Company or any of the Company
Subsidiaries is licensed or otherwise permitted by a third party to use any
Intellectual Property that is material to its business (except for any
“shrinkwrap” or “click through” license agreements or other agreements for
software that is generally available to the public and has not been customized
for the Company or the Company Subsidiaries) or under which a third party is
licensed or otherwise permitted to use any Intellectual Property owned by the
Company or any of the Company Subsidiaries;


    
      
         


      

      
        -15-

        
          

        

      

      
         


      

    


    (8)           any
contract that by its terms limits the payment of dividends or other
distributions by the Company or any Company Subsidiary;

     

    (9)           any
standstill or similar agreement pursuant to which the Company or any Company
Subsidiary has agreed not to acquire assets or securities of another
person;

     

    (10)           any
contract that would prevent, delay or impede the Company’s ability to consummate
the transactions contemplated by this Agreement and the Other Transaction
Documents;

     

    (11)           any
contract providing for indemnification by the Company or any Company Subsidiary
of any person, except for immaterial contracts entered into in the ordinary
course of business consistent with past practice;

     

    (12)           other
than contracts relating to the ordinary course management of credit extensions,
any contract that contains a put, call, or similar right pursuant to which the
Company or any Company Subsidiary could be required to purchase or sell, as
applicable, any equity interests or assets that have a fair market value or
purchase price of more than $250,000; and

     

    (13)           any
other contract or agreement which is a “material contract” within the meaning of
Item 601(b)(10) of Regulation S-K.

     

    Each of
the Company Significant Agreements is valid and binding on the Company and the
Company Subsidiaries, as applicable, and in full force and
effect.  The Company and each of the Company Subsidiaries, as
applicable, are in compliance in all material respects with and have performed
in all material respects all obligations required to be performed by them to
date under each Company Significant Agreement.  Neither the Company
nor any of the Company Subsidiaries knows of, or has received notice of, any
violation or default (or any condition which with the passage of time or the
giving of notice would cause such a violation of or a default) by any party
under any Company Significant Agreement.  Consummation of the
transactions contemplated by this Agreement will not place the Company or any of
the Company Subsidiaries in breach or default of any Company Significant
Agreement, or trigger any modification, termination or acceleration
thereunder.  Other than those contemplated hereby, there are no
transactions or series of related transactions, agreements, arrangements or
understandings, nor are there any currently proposed transactions, or series of
related transactions between the Company or any Company Subsidiaries, on the one
hand, and the Company, any current or former director or executive officer of
the Company or any Company Subsidiaries or any person who Beneficially Owns 5%
or more of the Common Shares (or any of such person’s immediate family members
or Affiliates) (other than Company Subsidiaries), on the other
hand.

     

    (l)           Offering of
Securities.  Neither the Company nor any person acting on its
behalf has taken any action (including, any offering of any securities of the
Company under circumstances which would require the integration of such offering
with the offering of any of the Common Stock to be issued pursuant to this
Agreement or any other Transaction Document under the Securities Act and the
rules and regulations of the SEC promulgated thereunder) which would subject the
offering, issuance, or sale of any of such Common Stock to be issued to the
registration requirements of the Securities Act.


    
      
         


      

      
        -16-

        
          

        

      

      
         


      

    


    (m)           Litigation and Other
Proceedings; No Undisclosed Liabilities.

     

    (1)           There
is no pending or, to the knowledge of the Company, threatened, claim, action,
suit, arbitration, mediation, demand, hearing, investigation or proceeding
against the Company or any Company Subsidiary that (A) involves a claim that is
or that could be, if adversely determined, for damages in excess of $100,000, or
(B) individually or in the aggregate, has prevented or materially impaired, or
would reasonably be expected to prevent or materially impair, the ability of the
Company to consummate the transactions contemplated hereby. Neither the Company
nor any Company Subsidiary is subject to any order, judgment or
decree.

     

    (2)           Neither
the Company nor any of the Company Subsidiaries has any liabilities or
obligations of any nature (absolute, accrued, contingent, or otherwise) which
are not appropriately reflected or reserved against in the financial statements
described in Section 2.2(f) to the extent required to be so reflected or
reserved against in accordance with GAAP, except for liabilities that have
arisen since September 30, 2009 in the ordinary course of business consistent
with past practice.

     

    (n)           Compliance with Laws and
Other Matters; Insurance.  Except as Previously Disclosed, the
Company and each Company Subsidiary:

     

    (1)           in
the conduct of its business is in compliance in all material respects with all,
and the condition and use of its properties does not violate or infringe in any
material respect any, applicable domestic (federal, state or local) or foreign
laws, statutes, ordinances, licenses, rules, regulations, judgments, demands,
writs, injunctions, orders or decrees applicable thereto or to employees
conducting its business, including the Troubled Asset Relief Program, the
Sarbanes-Oxley Act of 2002, the Equal Credit Opportunity Act, the Fair Housing
Act, the Community Reinvestment Act, the Home Mortgage Disclosure Act, the
Uniting and Strengthening America by Providing Appropriate Tools Required to
Intercept and Obstruct Terrorism (USA PATRIOT) Act of 2001, all other applicable
fair lending laws or other laws relating to discrimination and the Bank Secrecy
Act;

     

    (2)           has
all material permits, licenses, franchises, authorizations, orders, and
approvals of, and has made all filings, applications, and registrations with,
Governmental Entities that are required in order to permit it to own or lease
its properties and assets and to carry on its business as presently conducted
and that are material to the business of the Company or such Company Subsidiary;
and all such permits, licenses, certificates of authority, orders and approvals
are in full force and effect, and all such filings, applications and
registrations are current, and, to the knowledge of the Company, no suspension
or cancellation of any of them is threatened;

     

    (3)           currently
is complying in all material respects with and, to the knowledge of the Company,
is not under investigation with respect to, nor has been, threatened by any
Governmental Entity to be charged with or given notice of any material violation
of, all applicable federal, state, local and foreign laws, regulations, rules,
judgments, injunctions or decrees;


    
      
         


      

      
        -17-

        
          

        

      

      
         


      

    


    (4)           has,
except for statutory or regulatory restrictions of general application, not been
placed under any restriction by a Governmental Entity on its business or
properties, and except for routine examinations by applicable Governmental
Entities, as of the date of this Agreement, received no notification or
communication from any Governmental Entity that an investigation by any
Governmental Entity with respect to the Company or any of the Company
Subsidiaries is pending or threatened;

     

    (5)           has
not, since January 1, 2006 nor has any other person on behalf of the Company or
any Company Subsidiary that qualifies as a “financial institution” under the
U.S. Anti-Money Laundering laws, knowingly acted, by itself or in conjunction
with another, in any act in connection with the concealment of any currency,
securities or other proprietary interest that is the result of a felony as
defined in the U.S. Anti-Money Laundering laws (“Unlawful Gains”), nor
knowingly accepted, transported, stored, dealt in or brokered any sale, purchase
or any transaction of other nature for Unlawful Gains;

     

    (6)           to
the extent it qualifies as a “financial institution” under the U.S. Anti-Money
Laundering laws, has implemented such anti-money laundering mechanisms and kept
and filed all reports and other necessary documents as required by, and
otherwise complied with, the U.S. Anti-Money Laundering laws and the rules and
regulations thereunder; and

     

    (7)           is
presently insured, and during each of the past two calendar years (or during
such lesser period of time as the Company has owned such Company Subsidiary) has
been insured, for reasonable amounts with, to the knowledge of the Company,
financially sound and reputable insurance companies against such risks as
companies engaged in a similar business would, in accordance with industry
practice, customarily be insured.

     

    (o)           Labor.  Employees
of the Company and the Company Subsidiaries are not and have never been
represented by any labor union nor are any collective bargaining agreements
otherwise in effect with respect to such employees.  No labor
organization or group of employees of the Company or any Company Subsidiary has
made a pending demand for recognition or certification, and there are no
representation or certification proceedings or petitions seeking a
representation proceeding presently pending or, to the Company’s knowledge,
threatened to be brought or filed with the National Labor Relations Board or any
other labor relations tribunal or authority.  There are no organizing
activities, strikes, work stoppages, slowdowns, lockouts, arbitrations or
grievances, or other labor disputes pending or, to the knowledge of the Company,
threatened against or involving the Company or any Company
Subsidiary.  Each of the Company and the Company Subsidiaries are in
compliance in all material respects with all applicable laws respecting
employment and employment practices, terms and conditions of employment, and
wages and hours.

     

    (p)           Company Benefit
Plans.


    
      
         


      

      
        -18-

        
          

        

      

      
         


      

    


    (1)           “Benefit Plan” means all
employment agreements, employee benefit and compensation plans, programs,
agreements, contracts, policies, practices, or other arrangements providing
compensation or benefits to any current or former employee, officer, director or
consultant of the Company or any Company Subsidiary or any beneficiary or
dependent thereof that is sponsored or maintained by the Company or any Company
Subsidiary or to which the Company or any Company Subsidiary contributes or is
obligated to contribute or is party, whether or not written, including without
limitation any “employee welfare benefit plan” within the meaning of
Section 3(3) of the Employee Retirement Income Security Act of 1974, as
amended (“ERISA”), any
“employee pension benefit plan” within the meaning of Section 3(2) of ERISA
(whether or not such plan is subject to ERISA) and any bonus, incentive,
deferred compensation, vacation, stock purchase, stock appreciation right, stock
option or equity award, equity-based severance, employment, change of control,
consulting or fringe benefit plan, program, agreement or policy.  Each
Benefit Plan is listed on Section 2.2(p)(1) of the Company’s Disclosure
Schedule.  True and complete copies of all Benefit Plans listed on
Section 2.2(p)(1) of the Company’s Disclosure Schedule have been made
available to the Investor prior to the date hereof or have been filed with a
Company Report.

     

    (2)           With
respect to each Benefit Plan, (A) the Company and the Company Subsidiaries have
complied, and are now in compliance with the applicable provisions of ERISA, and
the Internal Revenue Code of 1986, as amended (the “Code”) and all other laws and
regulations applicable to such Benefit Plan and (B) each Benefit Plan has been
administered in accordance with its terms.  None of the Company or the
Company Subsidiaries nor any of their respective ERISA Affiliates has incurred
any withdrawal liability as a result of a complete or partial withdrawal from a
multiemployer plan, as those terms are defined in Part I of Subtitle E of Title
IV of ERISA, that has not been satisfied in full.  “ERISA Affiliate” means any
entity, trade or business, whether or not incorporated, which together with the
Company and the Company Subsidiaries, would be deemed a “single employer” within
the meaning of Section 4001 of ERISA or Sections 414(b), (c), (m) or
(o) of the Code.

     

    (3)           Each
Benefit Plan which is subject to ERISA (an “ERISA Plan”) that is an
“employee pension benefit plan” within the meaning of Section 3(2) of ERISA
(“Pension Plan”) and
that is intended to be qualified under Section 401(a) of the Code is so
qualified, has received a favorable determination letter from the IRS and
nothing has occurred, whether by action or failure to act, that could likely
result in revocation of any such favorable determination or opinion letter or
the loss of the qualification of such Benefit Plan under Section 401(a) of
the Code.  Neither the Company nor any Company Subsidiary has engaged
in a transaction with respect to any ERISA Plan that, assuming the taxable
period of such transaction expired as of the date hereof, could subject the
Company or any Company Subsidiary to a tax or penalty imposed by either
Section 4975 of the Code or Section 502(i) of
ERISA.  Neither the Company nor any Company Subsidiary has incurred or
reasonably expects to incur a material tax or penalty imposed by Section 4980F
of the Code or Section 502 of ERISA.


    
      
         


      

      
        -19-

        
          

        

      

      
         


      

    


    (4)           Neither
the Company, any Company Subsidiary nor any ERISA Affiliate (x) sponsors,
maintains or contributes to or has within the past six years sponsored,
maintained or contributed to a Pension Plan that is subject to Subtitles C or D
of Title IV of ERISA or (y) sponsors, maintains or has any liability with
respect to or an obligation to contribute to or has within the past six years
sponsored, maintained, had any liability with respect to, or had an obligation
to contribute to a “multiemployer plan” within the meaning of Section 3(37)
of ERISA.

     

    (5)           None
of the execution and delivery of this Agreement, the issuance of Common Stock,
nor the stockholder approval or consummation of the transactions contemplated
hereby, nor the transactions contemplated as part of the Other Private
Placements or the Public Offering, will, whether alone or in connection with
another event, (i) constitute a “change in control” or “change of control”
within the meaning of any Benefit Plan or result in any material payment or
benefit (including without limitation severance, unemployment compensation,
“excess parachute payment” (within the meaning of Section 280G of the
Code), forgiveness of indebtedness or otherwise) becoming due to any current or
former employee, officer, director or consultant of the Company or any Company
Subsidiary from the Company or any Company Subsidiary under any Benefit Plan or
any other agreement with any employee, including, for the avoidance of doubt,
any employment or change in control agreements, (ii) result in payments under
any of the Benefit Plans which would not be deductible under Section 162(m)
or Section 280G of the Code, (iii) materially increase any compensation or
benefits otherwise payable under any Benefit Plan, (iv) result in any
acceleration of the time of payment or vesting of any such benefits, including,
for the avoidance of doubt, the Company Stock Option Plans, (v) require the
funding or increase in the funding of any such benefits, or (vi) result in any
limitation on the right of the Company or any Company Subsidiary to amend,
merge, terminate or receive a reversion of assets from any Benefit Plan or
related trust.

     

    (6)           As
of the date hereof, there is no pending or, to the knowledge of the Company,
threatened, litigation relating to the Benefit Plans.  Neither the
Company nor any Company Subsidiary has any obligations for retiree health and
life benefits under any ERISA Plan or collective bargaining agreement, except
for health continuation coverage as required by Section 4980B of the Code
or Part 6 of Title I of ERISA and at no expense to the Company and the Company
Subsidiaries.

     

    (7)           There
are no pending or, to the knowledge of the Company, threatened claims, lawsuits
or arbitrations which have been asserted or instituted against (i) the Benefit
Plans, (ii) any fiduciaries thereof with respect to their duties to the Benefit
Plans, or (iii) the assets of any of the trusts under any of the Benefit
Plans.

     

    (q)           Status of
Securities.  Upon receipt of the Stockholder Approvals, the
shares of Common Stock to be issued pursuant to this Agreement and the other
Transaction Documents have been duly authorized by all necessary corporate
action of the Company.  When issued and sold against receipt of the
consideration therefor as provided in this Agreement and the other Transaction
Documents, such shares of Common Stock will be validly issued, fully paid and
nonassessable, and such issuance will not subject the holders thereof to
personal liability and will not be subject to preemptive rights of any other
stockholder of the Company.


    
      
         


      

      
        -20-

        
          

        

      

      
         


      

    


    (r)           Investment
Company.  Neither the Company nor any of the Company
Subsidiaries is an “investment company” as defined under the Investment Company
Act of 1940, as amended, and neither the Company nor any of the Company
Subsidiaries sponsors any person that is such an investment
company.

     

    (s)           Risk Management;
Derivatives.

     

    (1)           The
Company and the Company Subsidiaries have in place risk management policies and
procedures sufficient in scope and operation to protect against risks of the
type and in amounts expected to be incurred by persons of similar size and in
similar lines of business as the Company and the Company
Subsidiaries.

     

    (2)           All
derivative instruments, including swaps, caps, floors and option agreements,
whether entered into for the Company’s own account, or for the account of one or
more of the Company Subsidiaries or their customers, were entered into
(i) only for purposes of mitigating identified risk and in the ordinary
course of business, (ii) in accordance with prudent practices and in
material compliance with all applicable laws, rules, regulations and regulatory
policies, and (iii) with counterparties believed by the Company to be
financially responsible at the time; and each of them constitutes the valid and
legally binding obligation of the Company or one of the Company Subsidiaries,
enforceable in accordance with its terms.  Neither the Company nor the
Company Subsidiaries, nor, to the knowledge of the Company, any other party
thereto, is in breach of any of its obligations under any such agreement or
arrangement.

     

    (t)           Foreign Corrupt Practices
and International Trade Sanctions.  Neither the Company nor any
Company Subsidiary, nor any of their respective directors, officers, agents,
employees or any other persons acting on their behalf (i) has violated the
Foreign Corrupt Practices Act, 15 U.S.C. § 78dd-1 et seq., as amended, or any
other similar applicable foreign, federal, or state legal requirement,
(ii) has made or provided, or caused to be made or provided, directly or
indirectly, any payment or thing of value to a foreign official, foreign
political party, candidate for office or any other person knowing that the
person will pay or offer to pay the foreign official, party or candidate, for
the purpose of influencing a decision, inducing an official to violate their
lawful duty, securing any improper advantage, or inducing a foreign official to
use their influence to affect a governmental decision, (iii) has paid,
accepted or received any unlawful contributions, payments, expenditures or
gifts, (iv) has violated or operated in noncompliance with any export
restrictions, money laundering law, anti-terrorism law or regulation,
anti-boycott regulations or embargo regulations, or (v) is currently
subject to any United States sanctions administered by the Office of Foreign
Assets Control of the United States Treasury Department.

     

    (u)           Environmental
Liability.  There is no legal, administrative, or other
proceeding, claim or action of any nature seeking to impose, or that could
result in the imposition of, on the Company or any Company Subsidiary, any
liability relating to the release of hazardous substances as defined under any
local, state or federal environmental statute, regulation or ordinance,
including the Comprehensive Environmental Response, Compensation and Liability
Act of 1980, as amended, pending or, to the knowledge of the Company, threatened
against the Company or any Company Subsidiary; to the Company’s knowledge, there
is no reasonable basis for any such proceeding, claim or action; and to the
Company’s knowledge, neither the Company nor any Company Subsidiary is subject
to any agreement, order, judgment or decree by or with any Governmental Entity
or third party imposing any such environmental liability.


    
      
         


      

      
        -21-

        
          

        

      

      
         


      

    


    (v)           Anti-Takeover
Provisions.  The Company and the Board of Directors has taken
all actions necessary to ensure that the transactions contemplated by the
Transaction Documents or any of the transactions contemplated hereby or thereby,
taken as a whole, are not subject to the provisions of Section 60.835 of the
Oregon Business Corporation Act (the “OBCA”) (including, but not
limited to, the approval of such transactions by the Board of Directors and/or
stockholders as contemplated by Section 60.835 of the OBCA and Article X of the
Articles of Incorporation) and Article X of the Articles of Incorporation and
any other similar provisions of an anti-takeover nature contained in its
organizational documents and the provisions of any federal or state
“anti-takeover”, “fair price”, “moratorium”, “control share”, “supermajority”,
“affiliate transaction”, or “business combination” law, including any provisions
of the Oregon Business Corporation Act (each, a “Takeover Law”).  In
the case that such transactions are subject to such provisions or laws, the
Board of Directors shall take all necessary action to ensure that such
transactions shall be deemed to be exceptions to such provisions or laws,
including, but not limited to, the approval of such transactions as contemplated
under Section 60.835(1) of the OBCA.  The acquisition of the Common
Stock pursuant to the Transaction Documents and the consummation of the
transaction contemplated by the Transaction Documents is not a “control share
acquisition” or otherwise subject to the provisions of Section 60.801 to
Section 60.816 of the Oregon Business Corporation Act.

     

    (w)           Intellectual
Property.  (i) The Company and the Company Subsidiaries own
(free and clear of any claims, liens, encumbrances, exclusive licenses or
non-exclusive licenses not granted in the ordinary course of business) or have a
valid license to use all Intellectual Property used in or necessary to carry on
their business as currently conducted, and (ii) such Intellectual Property
referenced in clause (i) above is valid, subsisting and enforceable, and is not
subject to any outstanding order, judgment, decree or agreement adversely
affecting the Company’s or the Company Subsidiaries’ use of, or rights to, such
Intellectual Property.  The Company and the Company Subsidiaries have
sufficient rights to use all Intellectual Property used in their business as
presently conducted, all of which rights shall survive unchanged the
consummation of the transactions contemplated by this Agreement. Neither the
Company nor any Company Subsidiary has received any notice of infringement or
misappropriation of, or  any conflict with, the rights of others with
respect to any Intellectual Property, and no reasonable basis exists for any
such claim. To the Company’s knowledge, no third party has infringed,
misappropriated or otherwise violated the Intellectual Property rights of the
Company or the Company Subsidiaries. There is no litigation, opposition,
cancellation, proceeding, objection or claim pending, asserted, or, to the
Company’s knowledge, threatened against the Company or any Company Subsidiary
concerning the ownership, validity, registerability, enforceability,
infringement or use of, or licensed right to use, and Intellectual Property. To
the knowledge of the Company, none of  the Company or any of the
Company Subsidiaries is using or enforcing any  Intellectual Property
owned by or licensed to the Company or any of the Company Subsidiaries in a
manner that would be expected to result in the abandonment, cancellation or
unenforceability of such Intellectual Property.  The Company and each
of the Company Subsidiaries has taken all reasonable measures to protect the
Intellectual Property owned by or licensed to the Company or any of the Company
Subsidiaries.


    
      
         


      

      
        -22-

        
          

        

      

      
         


      

    


    “Intellectual Property” shall
mean trademarks, service marks, brand names, domain names, certification marks,
trade dress and other indications of origin, the goodwill associated with the
foregoing and registrations in any jurisdiction of, and applications in any
jurisdiction to register, the foregoing, including any extension, modification
or renewal of any such registration or application; inventions, discoveries and
ideas, whether patentable or not, in any jurisdiction; patents, applications for
patents (including divisions, continuations, continuations in part and renewal
applications), and any renewals, extensions or reissues thereof, in any
jurisdiction; nonpublic information, trade secrets and confidential information
and rights in any jurisdiction to limit the use or disclosure thereof by any
person; writings and other works, whether copyrightable or not, in any
jurisdiction; and registrations or applications for registration of copyrights
in any jurisdiction, and any renewals or extensions thereof; and any similar
intellectual property or proprietary rights.

     

    (x)           Brokers and
Finders.  Except for Keefe, Bruyette & Woods, Inc., neither
the Company nor any Company Subsidiary nor any of their respective officers,
directors or employees has employed any broker or finder or incurred any
liability for any financial advisory fees, brokerage fees, commissions or
finder’s fees, and no broker or finder has acted directly or indirectly for the
Company or any Company Subsidiary, in connection with the Transaction Documents
or the transactions contemplated hereby and thereby.

     

    (y)           Agreements with Regulatory
Agencies.  Except as Previously Disclosed, neither the Company
nor any Company Subsidiary is subject to any cease-and-desist or other similar
order or enforcement action issued by, or is a party to any written agreement,
consent agreement or memorandum of understanding with, or is a party to any
commitment letter or similar undertaking to, or is subject to any capital
directive by, or since December 31, 2007, has adopted any board resolutions at
the request of, any Governmental Entity that currently restricts the conduct of
its business or that relates to its capital adequacy, its liquidity and funding
policies and practices, its ability to pay dividends, its credit, risk
management or compliance policies, its internal controls, its management, or its
operations or business (each item in this sentence, a “Regulatory
Agreement”).  The Company and each Company Subsidiary are in
compliance with each Regulatory Agreement to which it is party or subject, and
neither the Company nor any Company Subsidiary has received any notice from any
Governmental Entity indicating that either the Company or any Company Subsidiary
is not in compliance with any such Regulatory Agreement.

     

    (z)           Loan
Portfolio.  The Company’s non-performing assets as of September
30, 2009 are $197,282,103.

     

    (aa)           Listing of Common
Stock.  The shares of Common Stock to be issued at the Closing
under this Agreement, the other Transaction Documents and the Public Offering
have been authorized, to the extent such Common Stock has been authorized under
the Articles of Incorporation, for listing on NASDAQ, subject to official notice
of issuance.

     

    (bb)           Directors’ and Officers’
Insurance. The Company (i) maintains directors’ and officers’
liability insurance and fiduciary liability insurance with financially sound and
reputable insurance companies with benefits and levels of coverage that have
been Previously Disclosed, (ii) has timely paid all premiums on such policies
and (iii) there has been no lapse in coverage during the term of such
policies.


    
      
         


      

      
        -23-

        
          

        

      

      
         


      

    


    (cc)           
Board of
Directors.  The Company does not have, and the Board of
Directors have not adopted, any policies, directives or resolutions, or any
amendments to the Company’s by-laws or certificate of incorporation, with
respect to qualification or other requirements for serving as a director on the
Board of Directors of the Company or any Subsidiary.

     

    (dd)           Other Private
Placements.  Concurrently with the execution and delivery of
this Agreement, the Company has agreed to sell Common Shares in the Other
Private Placements on the same economic and financial terms and conditions set
forth in this Agreement, with the closing of such Other Private Placements to
occur simultaneously with the Closing and the Public Offering.

     

    (ee)           Registration
Statements.  The Company’s registration statements, the
prospectuses forming a part of such registration statements and any amendments
thereto (including its registration statement on Form S-1 Reg. no. 333-162377,
filed on October 7, 2009, the prospectuses forming a part of such registration
statement and any amendments thereto), definitive proxy statements (including
the proxy statements to be filed in connection with the Stockholder Approvals)
filed or to be filed by it or any of the Company Subsidiaries subsequent to
December 31, 2008 under the Securities Act, or under Section 13(a), 13(c), 14 or
15(d) of the Exchange Act, in the form filed or as thereafter amended
(collectively, the “Company
SEC Filings”) with the SEC as of the date filed or amended prior to the
date hereof, as the case may be, (A) complied or will comply in all material
respects with the applicable requirements under the Securities Act or the
Exchange Act, as the case may be, and (B) did not and will not (for definitive
proxy statements, as of the date of filing with the SEC, and for registration
statements and the prospectuses contained therein, as of the time of sale as
defined in Rule 159 under the Securities Act) contain any untrue statement of a
material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading. Each of the statements
of financial position contained in or incorporated by reference into any of the
Company SEC Filings (including the related notes and schedules) fairly presented
or will fairly present in all material respects its financial position and that
of the Company Subsidiaries as of the date of such statement, and each of the
statements of income and changes in shareholders’ equity and cash flows or
equivalent statements in the Company SEC Filings (including any related notes
and schedules thereto) fairly presented or will fairly present in all material
respects, the results of operations, changes in shareholders’ equity and changes
in cash flows, as the case may be, of it and the Company Subsidiaries for the
periods to which those statements relate, in each case in accordance with GAAP
consistently applied during the periods involved, except in each case as may be
noted therein, and subject to normal year-end audit adjustments and as permitted
in the case of unaudited statements.

     

    (ff)           Approval by Continuing
Directors.  Two-thirds of the Continuing Directors (as defined
in the Articles of Incorporation) has voted in favor of the entering into of
this Agreement and the transactions contemplated by this Agreement, including
the issuance of shares, the increase in authorized shares and the reverse stock
split as described in the Company’s proxy statement filed pursuant to Section
14(a) of the Exchange Act on October 29, 2009 and has or will recommend approval
of the transactions contemplated by this Agreement to the Company’s
stockholders.


    
      
         


      

      
        -24-

        
          

        

      

      
         


      

    


    2.3           Representations and
Warranties of the Investor.  The Investor hereby represents and
warrants as of the date of this Agreement, solely with respect to himself and,
where expressly indicated, his Affiliates, to the Company that:

     

    (a)           Purchase for
Investment.  The Investor acknowledges that the Common Shares
have not been registered under the Securities Act or under any state securities
laws.  The Investor (1) is acquiring the Common Shares pursuant
to an exemption from registration under the Securities Act for his own account
solely for investment with no present intention or plan to distribute any of the
Common Shares to any person nor with a view to or for sale in connection with
any distribution thereof, (2) will not sell or otherwise dispose of any of
the Common Shares, except in compliance with the registration requirements or
exemption provisions of the Securities Act and any other applicable securities
laws, (3) has such knowledge and experience in financial and business
matters and in investments of this type that he is capable of evaluating the
merits and risks of his investment in the Common Shares and of making an
informed investment decision, and (4) is an “accredited investor” (as that
term is defined by Rule 501 of the Securities Act).  Without limiting
any of the foregoing, neither the Investor nor any of its Affiliates has taken,
and the Investor will not, and will cause his Affiliates not to, take any action
that would otherwise cause the Securities to be subject to the registration
requirements of the Securities Act.

     

    (b)           Financial
Capability.  The Investor will have immediately available funds
necessary to consummate the Closing, as of the date of the Closing, on the terms
and conditions contemplated by this Agreement.

     

    ARTICLE
III

     

    Covenants

     

    3.1           Filings; Other
Actions.

     

    (a)           The
Investor and the Company will cooperate and consult with each other and use
reasonable best efforts to prepare and file all necessary documentation, to
effect all necessary applications, notices, petitions, filings, and other
documents, and to obtain all necessary permits, consents, orders, approvals, and
authorizations of, or any exemption by, all third parties and Governmental
Entities, and expiration or termination of any applicable waiting periods,
necessary or advisable to consummate the transactions contemplated by this
Agreement, to perform covenants contemplated by this Agreement.  Each
party shall execute and deliver both before and after the Closing such further
certificates, agreements, and other documents and take such other actions as the
other party may reasonably request to consummate or implement such transactions
or to evidence such events or matters.  In particular, the Company
will use its reasonable best efforts to help the Investor promptly obtain or
submit, as the case may be, as promptly as practicable, the approvals and
authorizations of, filings and registrations with, and notifications to, or
expiration or termination of any applicable waiting period, all notices to and,
to the extent required by applicable law or regulation, consents, approvals, or
exemptions from bank regulatory authorities, for the transactions contemplated
by the Bolger Transaction Document.  The Investor and the Company will
each have the right to review in advance, and to the extent practicable, each
will consult with the other, in each case subject to applicable laws relating to
the exchange of information and confidential information related to the
Investor, all the information (other than confidential information) relating to
such other party, and any of their respective Affiliates, which appears in any
filing made with, or written materials submitted to, any third party or any
Governmental Entity in connection with the transactions contemplated by this
Agreement.  In exercising the foregoing right, each of the parties
hereto agrees to act reasonably and as promptly as practicable.  Each
party hereto agrees to keep the other party apprised of the status of matters
relating to completion of the transactions contemplated hereby.  The
Investor and the Company shall promptly furnish each other to the extent
permitted by applicable laws with copies of written communications received by
them or their subsidiaries from, or delivered by any of the foregoing to, any
Governmental Entity in respect of the transactions contemplated by this
Agreement or by any other Bolger Transaction
Document.  Notwithstanding the foregoing, the Investor shall not be
required to provide any materials to the Company that it deems private or
confidential nor shall be required to make any commitments to any Governmental
Entity in connection therewith or suffer any burdensome requirements or
restrictions in connection therewith.


    
      
         


      

      
        -25-

        
          

        

      

      
         


      

    


    (b)           The
Company shall call a special meeting of its stockholders, as promptly as
practicable, after the date of this Agreement to obtain the Stockholder
Approvals, including, without limitation, amending the Articles of Incorporation
to increase the number of authorized shares of Common Stock to 300 million,
approving the issuance of Common Shares for purposes of rule 5635 of NASDAQ’s
listing rules to the Investor and the investors participating in the Other
Private Placements.  The Board of Directors shall unanimously
recommend to the Company’s stockholders that such stockholders provide the
Stockholder Approvals, and shall not modify or withdraw such
resolution.  In connection with such meeting, the Company shall
promptly prepare (and the Investor will reasonably cooperate with the Company to
prepare) and file with the SEC a preliminary proxy statement, shall use its
reasonable best efforts to solicit proxies for such stockholder approval, and
shall use its reasonable best efforts to respond promptly to any comments of the
SEC or its staff and to cause a definitive proxy statement related to such
stockholders’ meeting to be mailed to the Company’s stockholders, as promptly as
practicable, after clearance by the SEC.  The Company shall notify the
Investor promptly of the receipt of any comments from the SEC or its staff with
respect to the proxy statement and of any request by the SEC or its staff for
amendments or supplements to such proxy statement or for additional information
and will supply the Investor with copies of all correspondence between the
Company or any of its representatives, on the one hand, and the SEC or its
staff, on the other hand, with respect to such proxy statement.  If at
any time prior to such stockholders’ meeting there shall occur any event that is
required to be set forth in an amendment or supplement to the proxy statement,
the Company shall, as promptly as practicable, prepare and mail to its
stockholders such an amendment or supplement.  The Investor and the
Company each agree to correct promptly any information provided by it or on its
behalf for use in the proxy statement if and to the extent that such information
shall have become false or misleading in any material respect, and the Company
shall, as promptly as practicable, prepare and mail to its stockholders an
amendment or supplement to correct such information to the extent required by
applicable laws and regulations.  The Company shall consult with the
Investor prior to mailing any proxy statement, or any amendment or supplement
thereto, and provide the Investor with reasonable opportunity to comment
thereon.  The directors’ recommendation described in this
Section 3.1 shall be included in the proxy statement filed in connection
with obtaining such stockholder approval.  Immediately upon approval
by stockholders of the increase in the Company’s authorized number of shares of
Common Stock as provided above, the Company shall file articles of amendment to
duly amend its Articles of Incorporation to include such
increase.


    
      
         


      

      
        -26-

        
          

        

      

      
         


      

    


    (c)           The
Company has filed a registration statement relating to the Public Offering with
the SEC (Registration No. 333-162377).  The Company shall promptly
prepare (and the Investor will reasonably cooperate with the Company to prepare)
and file with the SEC an amendment to the registration statement (including, for
purposes of this Section 3.1(c), the prospectuses forming a part thereof), and
shall use its reasonable best efforts to respond to any comments of the SEC or
its staff.  The Company shall notify the Investor promptly of the
receipt of any comments from the SEC or its staff with respect to the
registration statement and of any request by the SEC or its staff for amendments
or supplements to such registration statement or for additional information and
will supply the Investor with copies of all correspondence between the Company
or any of its representatives, on the one hand, and the SEC or its staff, on the
other hand, with respect to such registration statement.  If there
shall occur any event that is required to be set forth in an amendment or
supplement to the registration statement, the Company shall, as promptly as
practicable, prepare and file such an amendment or supplement.  The
Investor and the Company each agree to correct promptly any information provided
by it or on its behalf for use in the registration statement if and to the
extent that such information shall have become false or misleading in any
material respect, and the Company shall, as promptly as practicable, prepare and
file with the SEC an amendment or supplement to correct such information to the
extent required by applicable laws and regulations.  The Company shall
consult with the Investor prior to filing any registration statement, or any
amendment or supplement thereto, and provide the Investor with reasonable
opportunity to comment thereon.

     

    (d)           Each
party agrees, upon request, to furnish the other party with all information
concerning itself, its subsidiaries, Affiliates, directors, officers, partners,
and stockholders and such other matters as may be reasonably necessary or
advisable in connection with the proxy statement in connection with such
stockholders’ meeting and any other statement, filing, notice, or application
made by or on behalf of such other party or any of its subsidiaries to any
Governmental Entity in connection with the Bolger Transaction
Document.

     

    (e)           From
the date of this Agreement, until the Closing, the Company shall not, directly
or indirectly, amend, modify, or waive, and the Board of Directors shall not
recommend approval of any proposal to the stockholders having the effect of
amending, modifying, or waiving any provision in the Articles of Incorporation
or bylaws of the Company in any manner adverse to the Investor or any other
holder of Common Stock issued pursuant to this Agreement, including, for the
avoidance of doubt, any amendment, modification, or waiver that has the effect
of exempting any person (other than the Investor or any other holder of the
Securities issued pursuant to this Agreement) from the stock ownership
restrictions set forth in Article X of the Articles of
Incorporation.

     

    (f)           The
Company shall take all actions necessary to ensure that none of the execution
and delivery of this Agreement, nor the consummation of the transactions
contemplated hereby, nor the consummation of the transactions contemplated as
part of the Other Private Placements or the Public Offering, nor the Stockholder
Approvals will constitute a “change in control” or “change of control” within
the meaning of any Benefit Plan.


    
      
         


      

      
        -27-

        
          

        

      

      
         


      

    


    3.2           Expenses.  On
the earlier of the Closing Date and the termination of this Agreement, other
than a termination under circumstances that are directly and solely attributable
to a material breach by the Investor, the Company shall directly reimburse the
Investor for all out-of-pocket fees and expenses incurred in connection with due
diligence efforts, the negotiation and preparation of the Transaction Documents
and undertaking of the transactions contemplated by the Transaction Documents,
including, but not limited to, the Investor’s accounting, financial and
investment banking advisors, legal counsel and credit review, but excluding the
purchase or exercise price for any of the Securities), in an aggregate amount
not to exceed $1,250,000.  The Company shall be responsible for all
closing and annual administrative fees and expenses (including all costs
incurred to register the Registrable Securities and to obtain the Stockholder
Approvals, the fees and expenses of any Company advisors (including Company
counsel, the Company’s accounting and financial advisors and other professional
fees), SEC registration fees and related expenses, and fees and expenses of any
broker or finders.  Other than as set forth in this Section 3.2
and Section 4.7(b), each of the parties will
bear and pay all other costs and expenses incurred by it or him or on its or his
behalf in connection with the transactions contemplated under the Bolger
Transaction Document.

     

    3.3           Access, Information and
Confidentiality.

     

    (a)           From
the date of this Agreement, until the date when the shares of Common Stock owned
by the Investor in the aggregate represent less than 4.9% of all of the
outstanding Common Shares (counting for such purposes all shares of Common Stock
into or for which the Securities owned by the Investor are directly or
indirectly convertible or exercisable and excluding as shares owned and
outstanding all Common Shares issued by the Company after the Closing Date other
than as contemplated by this Agreement and the Securities), the Company will
ensure that upon reasonable notice, the Company and its subsidiaries will afford
to the Investor and his representatives (including employees of the Investor,
and counsel, accountants, financial and investment banking advisors and other
professionals retained by the Investor) such access during normal business hours
to its books, records, properties and personnel and to such other information as
the Investor may reasonably request.

     

    (b)           Each
party to this Agreement will hold, and will cause its respective subsidiaries
and their directors, officers, employees, agents, consultants, and advisors to
hold, in strict confidence, unless disclosure to a Governmental Entity is
necessary or appropriate in connection with any necessary regulatory approval or
unless compelled to disclose by judicial or administrative process or, in the
written opinion of its counsel, by other requirement of law or the applicable
requirements of any Governmental Entity, all nonpublic records, books,
contracts, instruments, computer data and other data and information
(collectively, “Information”) concerning the
other party hereto furnished to it by such other party or its representatives
pursuant to this Agreement (except to the extent that such information can be
shown to have been (1) previously known by such party on a nonconfidential
basis, (2) in the public domain through no fault of such party, or (3) later
lawfully acquired from other sources by the party to which it was furnished),
and neither party hereto shall release or disclose such Information to any other
person, except its auditors, attorneys, financial advisors, other consultants,
and advisors and, to the extent permitted above, to bank regulatory
authorities.


    
      
         


      

      
        -28-

        
          

        

      

      
         


      

    


    3.4           Transfer.

     

    (a)           At
Closing, the Company shall exchange each share of Common Stock presented for
such purpose by any of the Investor, Two-Forty, GRAT or CLAT, for a newly issued
share of Common Stock.  The newly issued shares of Common Stock issued
pursuant to this Section 3.4 shall not contain any restrictive legend unless
such legend appears on the shares of Common Stock issued pursuant to the
investment contemplated by this Agreement and pursuant to each Other Private
Placement.

     

    (b)           The
Company shall cooperate, to the full extent of, and in accordance with,
acceptable business practices, with any and all transfers, whether by direct or
indirect sale, assignment, award, confirmation, distribution, bequest, donation,
trust, pledge, encumbrance, hypothecation or other transfer or disposition, for
consideration or otherwise, whether voluntarily or involuntarily, by operation
of law or otherwise, by the Investor, Two-Forty, GRAT or CLAT  or any
of their respective successors and assigns of his or its Common Shares and other
shares of Common Stock such party may beneficially own prior to or subsequent to
the date hereof, or any legal or beneficial ownership therein, including voting
or economic interests therein and warrants, options or other rights to acquire
any of its Common Stock or legal beneficial ownership therein.

     

    3.5           Reasonable
Efforts.  The Company agrees to use its reasonable best efforts
to take, or cause to be taken, all actions, and to do, or cause to be done, and
to assist and cooperate with the Investor in doing, all things necessary, proper
or advisable to consummate and make effective, in the most expeditious manner
practicable, the transactions contemplated by this Agreement, the Other Private
Placements and the Public Offering, including using reasonable best efforts to
accomplish the following:  (a) the taking of all reasonable acts
necessary to cause the conditions to Closing to be satisfied; (b) the
mailing of the definitive proxy statement to the Company’s stockholders promptly
following clearance from the SEC; (c) the obtaining of all necessary
actions or nonactions, waivers, consents and approvals from Governmental
Entities and the making of all necessary registrations and filings and the
taking of all reasonable steps necessary to obtain an approval or waiver from,
or to avoid an action or proceeding by any Governmental Entity; (d) the
obtaining of all necessary consents, approvals or waivers from third parties;
(e) to cause the transactions contemplated by the Trust Preferred Securities
Repurchase Agreements to be consummated prior to the Closing Date; and
(f) the execution and delivery of any additional instruments necessary to
consummate the transactions contemplated by, and to fully carry out the purposes
of, this Agreement, the Other Private Placements and the Public
Offering.

     

    3.6           Conduct of the
Business.  Prior to the earlier of the Closing Date and the
termination of this Agreement pursuant to Section 5.1 (the “Pre-Closing Period”), the
Company shall, and shall cause each Company Subsidiary to, (i) conduct its
business in the ordinary course consistent with past practice, (ii) use
reasonable best efforts to preserve intact its current business organizations
and its rights and permits issued by Governmental Entities, keep available the
services of its current officers and key employees and preserve its
relationships with customers, suppliers, Governmental Entities and others having
business dealings with it to the end that its goodwill and ongoing businesses
shall be unimpaired and (iii) not take any action that would reasonably be
expected to materially adversely affect or materially delay the receipt of any
approvals of any Governmental Entity required to consummate the transactions
contemplated hereby or by the Other Transaction Agreements or materially
adversely affect or materially delay the consummation of the transactions
contemplated hereby or by the Other Transaction Agreements


    
      
         


      

      
        -29-

        
          

        

      

      
         


      

    


    3.7           Company
Forbearances.  During the Pre-Closing Period, the Company shall
not, and shall not permit any Company Subsidiary to:

     

    (a)           (i)
adjust, split, combine or reclassify any of its capital stock other than in
connection with the reverse stock split as described in the Company’s proxy
statement filed pursuant to Section 14(a) of the Exchange Act on October 29,
2009 affecting the Common Stock, the terms of which shall be subject to the
prior written consent of the Investor; (ii) set any record or payment dates for
the payment of any dividends or distributions on its capital stock or make,
declare or pay any dividend or make any other distribution on, or directly or
indirectly redeem, purchase or otherwise acquire, any shares of its capital
stock or any securities or obligations convertible into or exercisable or
exchangeable for any shares of its capital stock or stock appreciation rights or
grant any person any right to acquire any shares of its capital stock; or (iii)
issue or commit to issue any additional shares of capital stock (except pursuant
to the exercise of options and restricted stock unit grants outstanding as of
the date hereof and disclosed in the Company Disclosure Schedule), convertible
debt or any securities convertible into or exercisable or exchangeable for, or
any rights, warrants or options to acquire, any additional shares of capital
stock (including options) or convertible debt;

     

    (b)           
(i) increase the compensation or benefits of any employee of the Company or any
Company Subsidiary (except (x) for increases in salary or wages of employees of
the Company or any Company Subsidiary in the ordinary course of business
consistent with past practice, provided that no such
increase shall result in an annual adjustment of more than 5% of the aggregate
base salary and wages payable by the Company and its Subsidiaries during 2008
and (y) pursuant to the Company’s Benefit Plans as described on the Company’s
Disclosure Schedule; (ii) except as required by Law, grant any severance or
termination pay to any employee of the Company or any Company Subsidiary except
pursuant to the terms of any Plan in effect on the date of this Agreement and
which was made available to the Investor prior to the date of this Agreement and
disclosed in the Company’s Disclosure Schedule; (iii) loan or advance any money
or other property to any employees of the Company or any Company Subsidiary
other than in the ordinary course of business consistent with past practice;
(iv) (x) establish, adopt, enter into, amend or terminate, or (y) grant (other
than in the ordinary course of business consistent with past practice), any
waiver or consent under any Benefit Plan or any plan, agreement, program,
policy, trust, fund or other arrangement that would be a Benefit Plan if it were
in existence as of the date of this Agreement; or (v) grant any equity or
equity-based awards (including options and restricted stock units);

     

    
      
         


      

      
        -30-

        
          

        

      

      
         


      

    


    (c)           (i)  incur
any indebtedness for borrowed money, other than (x) deposit liabilities, FHLB
advances, advances from the Federal Reserve discount window, Fed funds purchases
and reverse repurchase agreements, in each case entered into in the ordinary
course of business consistent with past practice and, in the case of reverse
repurchase agreements, with a final maturity of five years or less, or (y)
indebtedness incurred in the ordinary course of business consistent with past
practice in order to finance working capital (subject in the case of this clause
(y) to an aggregate maximum amount of $5,000,000, (ii) guarantee, endorse or
assume responsibility for, the obligations of any person other than any
wholly-owned Subsidiary of the Company (other than the endorsement of checks and
other negotiable instruments in the normal process of collection) or (iii)
redeem, repurchase, prepay, defease, or cancel, or modify in any material
respect the terms of, indebtedness for borrowed money, other than (x) deposit
liabilities, FHLB advances and reverse repurchase agreements in each case in the
ordinary course of business consistent with past practice or (y) in accordance
with the terms of the applicable instrument as in effect on the date
hereof;

     

    (d)           settle
any action involving claims against the Company or any Company Subsidiary
resulting in monetary damages or other payments in excess of $100,000, agree or
consent to the issuance of any order restricting or otherwise affecting its
business or operations, or, in each case, that would cause the Company or any
Company Subsidiary to breach a representation, warranty or covenant contained in
this Agreement or would otherwise adversely affect the rights of the Investor
under this Agreement;

     

    (e)           amend
its certificate of incorporation, bylaws or similar governing documents (other
than for the purpose of effectuating the transactions contemplated by the
Transaction Documents), or enter into a plan of consolidation, merger, share
exchange, reorganization or complete or partial liquidation with any person
(other than consolidations, mergers or reorganizations solely among wholly-owned
Subsidiaries of the Company), or a letter of intent or agreement in principle
with respect thereto;

     

    (f)           make
any changes in its accounting methods or method of Tax accounting, practices or
policies, except as may be required under Law or GAAP, in each case following
consultation with the Company’s independent public accountants;

     

    (g)           except
as required by Law, make or change any Tax election, file any amended Tax
Returns, settle or compromise any material Tax liability of the Company or any
of its Subsidiaries, agree to an extension or waiver of the statute of
limitations with respect to the assessment or determination of Taxes of the
Company or any of its Subsidiaries, enter into any closing agreement with
respect to any Tax or surrender any right to claim a Tax refund; or

     

    (h)           agree
to, or make any commitment to, take any of the actions prohibited by this
Section 3.7 or that would otherwise materially adversely affect or materially
delay the consummation of the transactions contemplated hereby or by the other
Transaction Documents.

     

    3.8           Shareholder
Litigation.  The Company shall promptly inform Investor of any
claim, action, suit, arbitration, mediation, demand, hearing, investigation or
proceeding (“Shareholder
Litigation”) against the Company, any Company Subsidiary or any of the
past or present executive officers or directors of the Company or any Company
Subsidiary that is threatened or initiated by or on behalf of any stockholder of
the Company in connection with or relating to the Order, the Public Offering or
the transactions contemplated hereby or by the Transaction
Documents.  The Company shall consult with Investor and keep Investor
informed of all material filings and developments relating to any such
Shareholder Litigation.


    
      
         


      

      
        -31-

        
          

        

      

      
         


      

    

     

    ARTICLE
IV

     

    Additional
Agreements

     

    4.1           No Rights
Agreement.  From the date hereof through such time during which
the Investor owns at least 5% of the outstanding shares of Common Stock of the
Company, the Company shall not enter into any poison pill agreement,
stockholders’ rights plan or similar agreement that shall limit the rights of
the Investor and his Affiliates and associates to hold any shares of Common
Stock or acquire additional securities of the Company unless such poison pill
agreement, stockholders’ rights plan or similar agreement grants an exemption or
waiver to the Investor and his affiliates and associates and any group in which
the Investor may become a member of, immediately effective upon execution of
such plan or agreement that would allow the Investor and his Affiliates and
associates to acquire such additional securities of the Company.

     

    4.2           Governance
Matters.

     

    (a)           For
so long as the Investor, together with his Affiliates, owns at least 10% or more
of all of the outstanding shares of Common Stock, the Investor shall have the
right to nominate two candidates for election to each of the Board of Directors
and the board of directors of Bank of the Cascades (the “Company Bank”), an Oregon
chartered stock bank and a wholly owned subsidiary of the Company, as candidates
recommended by the Board of Directors, unless both Investor Nominees are still
serving as Directors on each board and will continue to serve after the relevant
election.  For as long as the Investor, together with his Affiliates,
owns at least 5% but less than 10% of all of the outstanding shares of Common
Stock, the Investor shall have the right to nominate one candidate for election
to each of the Board of Directors and the board of directors of the Company Bank
as a candidate recommended by the Board of Directors, unless an Investor Nominee
is still serving as a Director on each board and will continue to serve after
the relevant election.  In all cases, the Company shall cause the
nominee or designee to be elected a Director of the Board of Directors and the
board of directors of the Company Bank.  Notwithstanding anything to
the contrary in the Articles of Incorporation, bylaws, or any other policies of
the Company, the Company Bank, the Board of Directors or the board of directors
of the Company Bank, Investor Nominees shall be elected by plurality of the
votes cast by the Common Shares entitled to vote at a meeting at which a quorum
is present.  Any person nominated or designated pursuant to this
Section 4.2 shall be an “Investor
Nominee”.  Investor Nominee shall also include any director
referred to in Section 3.01 of the Shareholders Agreement.

     

    (b)           Notwithstanding
anything to the contrary contained herein, if any Investor Nominee resigns or is
unable to continue to serve as a Director of the Company or as a Director of the
Company Bank, the Investor may designate a replacement Director and the relevant
board of directors shall elect such person a Director; provided, however, that in each case,
the Investor remains entitled to nominate and designate Directors pursuant to
this Section 4.2 and such action is taken in accordance with this Section 4.2;
and provided further,
however, that the
replacement Director designated pursuant to this Section 4.2(b) must be
reasonably acceptable to the remaining members of the Board of Directors (or
nominating committee thereof), and, without the consent of the Board of
Directors (or nominating committee thereof), shall not include any individual
who is an Affiliate of a competitor of the Company.


    
      
         


      

      
        -32-

        
          

        

      

      
         


      

    


    (c)           Any
Director of the Company may be removed from the Board of Directors or from the
board of directors of the Company Bank in accordance with applicable law and the
governing documents of the Company or of the Company Bank, as applicable; provided, however, that with respect to
a Director nominated or designated pursuant to this Section 4.2, any such
removal shall require the prior written consent of the Investor unless such
removal is required by applicable law or such Director is no longer qualified to
serve as a Director pursuant to applicable SEC or regulatory requirements, or a
generally applicable policy of the Board of Directors.

     

    (d)           Any
vacancies on the Board of Directors and on the board of directors of the Company
Bank shall be filled in accordance with the applicable bylaws and, if the
vacancy is with respect to a Director originally nominated or designated by the
Investor, this Section 4.2.

     

    (e)           The
Company, the Board of Directors and the board of directors of the Company Bank
shall ensure that any Directors nominated or designated pursuant to this Section
4.2 or the Shareholders Agreement, dated December 27, 2005, by and among
the Company, the Investor and the parties listed on Schedule A thereto (the
“Shareholders
Agreement”) shall enjoy the same rights, capacities, entitlements and
compensation as any other members of the Board of Directors and the board of
directors of Company Bank, as applicable.

     

    (f)           Effective
as of the next annual meeting of shareholders following the date of this
Agreement, the number of directors on the Board of Directors shall not exceed
nine (9).

     

    (g)           
The Company and the Board of Directors shall not take any action that would
result in any amendment to the governing documents of the Company or the Company
Bank inconsistent with the provisions of this Section 4.2.

     

    (h)           For
so long as the Investor, together with his Affiliates, owns 5% or more of all of
the outstanding shares of Common Stock, the Company shall not amend its
governing documents to amend the current mandatory retirement age for the Board
of Directors.

     

    (i)           The
Company and the Board of Directors shall not take any action that would result
in a change in status of the Investor as a “Director Emeritus.” The privileges
and entitlements of the post “Director Emeritus” shall be established from time
to time by the Board of Directors but shall include recognition of the Director
Emeritus’ past contributions at annual shareholders’ meetings and sponsored
public events where they are in attendance, and an invitation to the annual
board/management dinner and other events in the Board of Director’s
discretion.  A Director Emeritus, however, will have no voting
authority, will not receive any form of compensation and will not be an attendee
at Board of Director meetings.

     

    (j)           The
Investor shall not nominate himself to serve as a Director of the Company or the
Company Bank and shall not accept any such appointment or
nomination.


    
      
         


      

      
        -33-

        
          

        

      

      
         


      

    

    4.3           Legend.

     

    (a)           The
Investor agrees that all certificates or other instruments representing the
Securities subject to this Agreement will bear a legend substantially to the
following effect:

     

    “THE
SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR SECURITIES LAWS OF ANY STATE AND MAY NOT
BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT WHILE A REGISTRATION
STATEMENT RELATING THERETO IS IN EFFECT UNDER SUCH ACT AND APPLICABLE STATE
SECURITIES LAWS OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT OR
SUCH LAWS.”

     

    (b)           Upon
request of the Investor, upon receipt by the Company of an opinion of counsel
reasonably satisfactory to the Company to the effect that such legend is no
longer required under the Securities Act or applicable state laws, as the case
may be, the Company shall promptly cause the legend to be removed from any
certificate for any Securities.  The Investor acknowledges that the
Securities have not been registered under the Securities Act or under any state
securities laws and agrees that he will not sell or otherwise dispose of any of
the Securities, except in compliance with the registration requirements or
exemption provisions of the Securities Act and any other applicable securities
laws.

     

    4.4           [Reserved]

     

    4.5           Certain
Transactions.  The
Company will not merge or consolidate into, or sell, transfer or lease all or
substantially all of its property or assets to, any other party unless the
successor, transferee or lessee party, as the case may be (if not the Company),
expressly assumes the due and punctual performance and observance of each and
every covenant and condition of this Agreement to be performed and observed by
the Company.

     

    4.6           Indemnity.

     

    (a)           The
Company agrees to indemnify and hold harmless the Investor and his Affiliates
and each of their respective officers, directors, partners, employees and
agents, to the fullest extent lawful, from and against any and all actions,
suits, claims, proceedings, costs, losses, liabilities, damages, expenses
(including attorneys’ fees and disbursements), amounts paid in settlement and
other costs (collectively, “Losses”) arising out of or
resulting from (1) any inaccuracy in or breach of the Company’s
representations or warranties in Section 2.2 of this Agreement,
(2) the Company’s breach of agreements or covenants made by the Company in
this Agreement or (3) any Losses arising out of or resulting from any
legal, administrative or other proceedings instituted by any Governmental
Entity, stockholder of the Company or any other person (other than the Investor
and his Affiliates and the Company and the Company Subsidiaries) arising out of
the transactions contemplated by this Agreement and the terms of the Securities
(other than any Losses attributable to the acts, errors or omissions on the part
of the Investor, but not including the transactions contemplated
hereby).


    
      
         


      

      
        -34-

        
          

        

      

      
         


      

    


    (b)           The
Investor agrees to indemnify and hold harmless each of the Company and its
Affiliates and each of their respective officers, directors, partners, employees
and agents, to the fullest extent lawful, from and against any and all Losses
arising out of or resulting from (1) any inaccuracy in or breach of the
Investor’s representations or warranties in this Agreement or (2) the
Investor’s breach of agreements or covenants made by the Investor in this
Agreement.

     

    (c)           A
party entitled to indemnification hereunder (each, an “Indemnified Party”) shall
give written notice to the party indemnifying it (the “Indemnifying Party”) of any
claim with respect to which it seeks indemnification promptly after the
discovery by such Indemnified Party of any matters giving rise to a claim for
indemnification; provided that the failure of
any Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Section 4.6 unless and to the
extent that the Indemnifying Party shall have been actually prejudiced by the
failure of such Indemnified Party to so notify such party.  Such
notice shall describe in reasonable detail such claim.  In case any
such action, suit, claim or proceeding is brought against an Indemnified Party,
the Indemnified Party shall be entitled to hire, at the cost and expense of the
Indemnifying Party counsel and conduct the defense thereof; provided, however, that the
Indemnifying Party shall only be liable for the legal fees and expenses of one
law firm for all Indemnified Parties, taken together with regard to any single
action or group of related actions, upon agreement by the Indemnified Parties
and the Indemnifying Parties.  If the Indemnifying Party assumes the
defense of any claim, all Indemnified Parties shall thereafter deliver to the
Indemnifying Party copies of all notices and documents (including court papers)
received by the Indemnified Party relating to the claim, and any Indemnified
Party shall cooperate in the defense or prosecution of such
claim.  Such cooperation shall include the retention and (upon the
Indemnifying Party’s request) the provision to the Indemnifying Party of records
and information that are reasonably relevant to such claim, and making employees
available on a mutually convenient basis to provide additional information and
explanation of any material provided hereunder.  The Indemnifying
Party shall not be liable for any settlement of any action, suit, claim or
proceeding effected without its written consent; provided, however, that the
Indemnifying Party shall not unreasonably withhold, delay or condition its
consent.  The Indemnifying Party further agrees that it will not,
without the Indemnified Party’s prior written consent (which shall not be
unreasonably withheld or delayed), settle or compromise any claim or consent to
entry of any judgment in respect thereof in any pending or threatened action,
suit, claim or proceeding in respect of which indemnification has been sought
hereunder unless such settlement or compromise includes an unconditional release
of such Indemnified Party from all liability arising out of such action, suit,
claim or proceeding.

     

    (d)           For
purposes of the indemnity contained in Sections 4.6(a)(1) and 4.6(b)(1),
all qualifications and limitations set forth in the parties’ representations and
warranties as to “materiality,” “Material Adverse Effect” and words of similar
import, shall be disregarded in determining whether there shall have been any
inaccuracy in or breach of any representations and warranties in this
Agreement.


    
      
         


      

      
        -35-

        
          

        

      

      
         


      

    


    (e)           The
Company shall not be required to indemnify the Indemnified Parties pursuant to
Section 4.6(a)(1), disregarding all qualifications or limitations set forth in
such representation and warranties as to “materiality,” “Material Adverse
Effect” and words of similar import, (1) with respect to any claim for
indemnification if the amount of Losses with respect to such claim are less than
$50,000 (any claim involving Losses less than such amount being referred to as a
“De Minimis Claim”) and
(2) unless and until the aggregate amount of all Losses incurred with respect to
all claims (other than De Minimis Claims) pursuant to Section 4.6(a)(1) exceed
$250,000 (the “Threshold
Amount”), in which event the Company shall be responsible for the entire
amount of such Losses.  No Investor shall be required to indemnify the
Indemnified Parties pursuant to Section 4.6(b)(1), disregarding all
qualifications or limitations set forth in such representation and warranties as
to “materiality,” “Material Adverse Effect” and words of similar import, (1)
with respect to any De Minimis Claim and (2) unless and until the aggregate
amount of all Losses incurred with respect to all claims (other than De Minimis
Claims) pursuant to Section 4.6(b)(1) exceed the Threshold Amount, in which
event such Investor shall be responsible for the entire amount of such
Losses.

     

    (f)           The
obligations of the Indemnifying Party under this Section 4.6 shall survive the
transfer or redemption of the Common Stock issued pursuant to this Agreement, or
the Closing or termination of the Bolger Transaction Document; provided that in the event of
any transfer of the Common Stock to a third party that is not an Affiliate of
the transferor, the Indemnifying Party shall have no obligations under this
Section 4.6 to
such transferee.  The indemnity provided for in this Section 4.6 shall be the sole
and exclusive monetary remedy of Indemnified Parties after the Closing for any
inaccuracy of any of the representations and warranties contained in
Sections 2.2 and Sections 2.3 of this Agreement or any other breach of
any covenant or agreement contained in this Agreement; provided that nothing herein
shall limit in any way any such parties’ remedies in respect of fraud,
intentional misrepresentation or omission or intentional misconduct by the other
party in connection with the transactions contemplated hereby.  No
party to this Agreement (or any of its Affiliates) shall, in any event, be
liable or otherwise responsible to any other party (or any of its Affiliates)
for any consequential or punitive damages of such other party (or any of its
Affiliates) arising out of or relating to this Agreement or the performance or
breach hereof.  The indemnification rights contained in this
Section 4.6 are
not limited or deemed waived by any investigation or knowledge by the
Indemnified Party prior to or after the date hereof.

     

    (g)           Any
indemnification payments pursuant to this Section 4.6 shall be treated as
an adjustment to the Purchase Price for the Securities for U.S. federal income
and applicable state and local Tax purposes, unless a different treatment is
required by applicable law.

     

    4.7           Registration
Rights.

     

    (a)           Registration.

     

    (1)           Subject
to the terms and conditions of this Agreement, the Company covenants and agrees
that as promptly as practicable after the Closing Date (and in any event no
later than the date that is 30 days after the Closing Date (the “Registration Deadline”)), the
Company shall have prepared and filed with the SEC a Shelf Registration
Statement (defined below) covering all Registrable Securities (or otherwise
designate an existing Shelf Registration Statement filed with the SEC to cover
the Registrable Securities), and, to the extent the Shelf Registration Statement
has not theretofore been declared effective or is not automatically effective
upon such filing, the Company shall use reasonable best efforts to cause such
Shelf Registration Statement to be declared or become effective not later than
the Registration Deadline and to keep such Shelf Registration Statement
continuously effective and in compliance with the Securities Act and usable for
resale of such Registrable Securities for a period from the date of its initial
effectiveness until such time as there are no Registrable Securities remaining
(including by refiling such Shelf Registration Statement (or a new Shelf
Registration Statement) if the initial Shelf Registration Statement
expires).  If the Company is a well-known seasoned issuer (as defined
in Rule 405 under the Securities Act) at the time of filing of the Shelf
Registration Statement with the SEC, such Shelf Registration Statement shall be
designated by the Company as an automatic Shelf Registration
Statement.


    
      
         


      

      
        -36-

        
          

        

      

      
         


      

    

     

    (2)           Any
registration pursuant to this Section 4.7(a) shall be
effected by means of a shelf registration under the Securities Act (a “Shelf Registration
Statement”) in accordance with the methods and distribution set forth in
the Shelf Registration Statement and Rule 415.  If the Investor or any
other Holder of Registrable Securities to whom the registration rights conferred
by this Agreement have been transferred in compliance with this Agreement
intends to distribute any Registrable Securities by means of an underwritten
offering it shall promptly so advise the Company and the Company shall take all
reasonable steps to facilitate such distribution, including the actions required
pursuant to Section 4.7(c); provided, that the Company
shall not be required to facilitate an underwritten offering of Registrable
Securities unless the expected gross proceeds from such offering exceed
$1,000,000.  The lead underwriters in any such distribution shall be
selected by the holders of a majority of the Registrable Securities to be
distributed and be reasonably acceptable to the Company.

     

    (3)           The
Company shall not be required to effect a registration (including a resale of
Registrable Securities from an effective Shelf Registration Statement) or an
underwritten offering pursuant to this Section 4.7(a):  (i)
with respect to securities that are not Registrable Securities; (ii) during any
Scheduled Black-out Period; or (iii) if the Company has notified the Investor
and all other Holders that in the good faith judgment of the Board of Directors,
it would be materially detrimental to the Company or its security holders for
such registration or underwritten offering to be effected at such time, in which
event the Company shall have the right to defer such registration or
underwritten offering for a period of not more than 30 days after receipt of the
request of the Investor or any other Holder; provided that such right to
delay a registration or underwritten offering shall be exercised by the Company
(A) only if the Company has generally exercised (or is concurrently exercising)
similar black-out rights against holders of similar securities that have
registration rights and (B) not more than twice in any 12-month period and not
more than 60 days in the aggregate in any 12-month period.


    
      
         


      

      
        -37-

        
          

        

      

      
         


      

    


    (4)           After
the Closing Date, whenever the Company proposes to register any of its equity
securities, other than a registration pursuant to Section 4.7(a)(1) or a Special
Registration, and the registration form to be filed may be used for the
registration or qualification for distribution of Registrable Securities, the
Company will give prompt written notice to the Investor and all other Holders of
its intention to effect such a registration (but in no event less than 15 days
prior to the anticipated filing date) and (subject to clause (6) below) will
include in such registration all Registrable Securities with respect to which
the Company has received written requests for inclusion therein within ten
business days after the date of the Company’s notice (a “Piggyback
Registration”).  Any such person that has made such a written
request may withdraw its Registrable Securities from such Piggyback Registration
by giving written notice to the Company and the managing underwriter, if any, on
or before the fifth day prior to the planned effective date of such Piggyback
Registration. The Company may terminate or withdraw any registration under this
Section 4.7(a)(4)
prior to the effectiveness of such registration, whether or not the Investor or
any other Holders have elected to include Registrable Securities in such
registration.  “Special Registration” means
the registration of (i) equity securities and/or options or other rights in
respect thereof solely registered on Form S-4 or Form S-8 (or successor form) or
(ii) shares of equity securities and/or options or other rights in respect
thereof to be offered to directors, members of management, employees,
consultants, customers, lenders or vendors of the Company or Company
Subsidiaries or in connection with dividend reinvestment plans.

     

    (5)           If
the registration referred to in Section 4.7(a)(4) is proposed
to be underwritten, the Company will so advise the Investor and all other
Holders as a part of the written notice given pursuant to Section 4.7(a)(4).  In
such event, the right of the Investor and all other Holders to registration
pursuant to this Section 4.7(a) will be
conditioned upon such persons’ participation in such underwriting and the
inclusion of such persons’ Registrable Securities in the underwriting, and each
such person will (together with the Company and the other persons distributing
their securities through such underwriting) enter into an underwriting agreement
in customary form with the underwriter or underwriters selected for such
underwriting by the Company.  If any participating person disapproves
of the terms of the underwriting, such person may elect to withdraw therefrom by
written notice to the Company, the managing underwriter and the
Investor.

     

    (6)           The
Company represents and warrants that it has not granted to any holder of its
securities and agrees that it shall not grant “piggyback” registration rights to
one or more third parties to include their securities in the Shelf Registration
Statement or in an underwritten offering under the Shelf Registration Statement
pursuant to Section 4.7(a)(2).  If
a Piggyback Registration under Section 4.7(a)(4) relates to an
underwritten primary offering on behalf of the Company, and in either case the
managing underwriters advise the Company that in their reasonable opinion the
number of securities requested to be included in such offering exceeds the
number which can be sold without adversely affecting the marketability of such
offering (including an adverse effect on the per share offering price), the
Company will include in such registration or prospectus only such number of
securities that in the reasonable opinion of such underwriters can be sold
without adversely affecting the marketability of the offering (including an
adverse effect on the per share offering price), which securities will be so
included in the following order of priority: (i) first, in the case of a
Piggyback Registration under Section 4.7(a)(4), the
securities the Company proposes to sell, (ii) second, Registrable Securities of
the Investor and all other Holders who have requested registration of
Registrable Securities pursuant to Section 4.7(a)(2) or 4.7(a)(4), as
applicable, pro rata on
the basis of the aggregate number of such securities or shares owned by each
such person and (iii) third, any other securities of the Company that have been
requested to be so included, subject to the terms of this
Agreement.


    
      
         


      

      
        -38-

        
          

        

      

      
         


      

    

     

    (b)           Expenses of
Registration.  All Registration Expenses incurred in connection
with any registration, qualification or compliance hereunder shall be borne by
the Company.  The Company shall bear its internal expenses (including,
without limitation, all salaries and expenses of their officers and employees
performing legal, accounting or other duties) and expenses of any person,
including special experts, retained by the Company.  The Company shall
also reimburse the Investor for the reasonable fees and disbursements of legal
counsel to the Investor in an amount not to exceed $25,000 per
registration.  All Selling Expenses incurred in connection with any
registrations hereunder shall be borne by the holders of the securities so
registered pro rata on
the basis of the aggregate offering or sale price of the securities so
registered.

     

    (c)           Obligations of the
Company.  The Company shall use its reasonable best efforts for
so long as there are Registrable Securities outstanding, to take such actions as
are under its control to remain a well-known seasoned issuer (as defined in Rule
405 under the Securities Act) if it becomes eligible for such status in the
future (and not become an ineligible issuer (as defined in Rule 405 under the
Securities Act)).  In addition, whenever required to effect the
registration of any Registrable Securities or facilitate the distribution of
Registrable Securities pursuant to an effective Shelf Registration Statement,
the Company shall, as expeditiously as reasonably practicable:

     

    (1)           Prepare
and file with the SEC a prospectus supplement with respect to a proposed
offering of Registrable Securities pursuant to an effective registration
statement, subject to this Section 4.7(c), and keep such
registration statement effective or such prospectus supplement current until the
securities described therein are no longer Registrable Securities.

     

    (2)           Prepare
and file with the SEC such amendments and supplements to the applicable
registration statement and the prospectus or prospectus supplement used in
connection with such registration statement as may be necessary to comply with
the provisions of the Securities Act with respect to the disposition of all
securities covered by such registration statement.

     

    (3)           Furnish
to the Holders and any underwriters such number of copies of the applicable
registration statement and each such amendment and supplement thereto (including
in each case all exhibits) and of a prospectus, including a preliminary
prospectus, in conformity with the requirements of the Securities Act, and such
other documents as they may reasonably request in order to facilitate the
disposition of Registrable Securities owned or to be distributed by
them.

     

    (4)           Use
its reasonable best efforts to register and qualify the securities covered by
such registration statement under such other securities or blue sky laws of such
jurisdictions as shall be reasonably requested by the Holders or any managing
underwriter(s), to keep such registration or qualification in effect for so long
as such registration statement remains in effect, and to take any other action
which may be reasonably necessary to enable such seller to consummate the
disposition in such jurisdictions of the securities owned by such Holder; provided that the Company
shall not be required in connection therewith or as a condition thereto to
qualify to do business or to file a general consent to service of process in any
such states or jurisdictions.


    
      
         


      

      
        -39-

        
          

        

      

      
         


      

    

     

    (5)           Notify
each Holder of Registrable Securities at any time when a prospectus relating
thereto is required to be delivered under the Securities Act of the happening of
any event as a result of which the applicable prospectus, as then in effect,
includes an untrue statement of a material fact or omits to state a material
fact required to be stated therein or necessary to make the statements therein
not misleading in light of the circumstances then existing.

     

    (6)           Give
written notice to the Holders:

     

    (i)           when
any registration statement filed pursuant to Section 4.7(a) or any amendment
thereto has been filed with the SEC (except for any amendment effected by the
filing of a document with the SEC pursuant to the Exchange Act) and when such
registration statement or any post-effective amendment thereto has become
effective;

     

    (ii)           of
any request by the SEC for amendments or supplements to any registration
statement or the prospectus included therein or for additional
information;

     

    (iii)           of
the issuance by the SEC of any stop order suspending the effectiveness of any
registration statement or the initiation of any proceedings for that
purpose;

     

    (iv)           of
the receipt by the Company or its legal counsel of any notification with respect
to the suspension of the qualification of the Common Stock for sale in any
jurisdiction or the initiation or threatening of any proceeding for such
purpose;

     

    (v)           of
the happening of any event that requires the Company to make changes in any
effective registration statement or the prospectus related to the registration
statement in order to make the statements therein not misleading (which notice
shall be accompanied by an instruction to suspend the use of the prospectus
until the requisite changes have been made); and

     

    (vi)           if
at any time the representations and warranties of the Company contained in any
underwriting agreement contemplated by Section 4.7(c)(10) cease to be
true and correct.

     

    (7)           Use
its reasonable best efforts to prevent the issuance or obtain the withdrawal of
any order suspending the effectiveness of any registration statement referred to
in Section 4.7(c)(6)(iii) at the
earliest practicable time.


    
      
         


      

      
        -40-

        
          

        

      

      
         


      

    


    (8)           Upon
the occurrence of any event contemplated by Section 4.7(c)(5) or
4.7(c)(6)(v), promptly prepare a post-effective amendment to such registration
statement or a supplement to the related prospectus or file any other required
document so that, as thereafter delivered to the Holders and any underwriters,
the prospectus will not contain an untrue statement of a material fact or omit
to state any material fact necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading.  If the
Company notifies the Holders in accordance with Section 4.7(c)(6)(v) to suspend
the use of the prospectus until the requisite changes to the prospectus have
been made, then the Holders and any underwriters shall suspend use of such
prospectus and use their reasonable best efforts to return to the Company all
copies of such prospectus (at the Company’s expense) other than permanent file
copies then in such Holder’s or underwriter’s possession.  The total
number of days that any such suspension may be in effect in any 180-day period
shall not exceed 30 days.

     

    (9)           Use
best efforts to procure the cooperation of the Company’s transfer agent in
settling any offering or sale of Registrable Securities, including with respect
to the transfer of physical stock certificates into book-entry form in
accordance with any procedures reasonably requested by the Holders or any
managing underwriter(s).

     

    (10)           If
an underwritten offering is requested pursuant to Section 4.7(a)(2), enter into
an underwriting agreement in customary form, scope and substance and take all
such other actions reasonably requested by the Holders of a majority of the
Registrable Securities being sold in connection therewith or by the managing
underwriter(s), if any, to expedite or facilitate the underwritten disposition
of such Registrable Securities, and in connection therewith in any underwritten
offering (including making members of management and executives of the Company
available to participate in “road shows,” similar sales events and other
marketing activities), (i) make such representations and warranties to the
Holders that are selling stockholders and the managing underwriter(s), if any,
with respect to the business of the Company and its subsidiaries, and the Shelf
Registration Statement, prospectus and documents, if any, incorporated or deemed
to be incorporated by reference therein, in each case, in customary form,
substance and scope, and, if true, confirm the same if and when requested, (ii)
furnish the underwriters with opinions of counsel to the Company, addressed to
the managing underwriter(s), if any, covering the matters customarily covered in
such opinions requested in underwritten offerings, (iii) obtain “comfort”
letters from the independent certified public accountants of the Company (and,
if necessary, any other independent certified public accountants of any business
acquired by the Company for which financial statements and financial data are
included in the Shelf Registration Statement) who have certified the financial
statements included in such Shelf Registration Statement, addressed to each of
the managing underwriter(s), if any, such letters to be in customary form and
covering matters of the type customarily covered in “comfort” letters, (iv) if
an underwriting agreement is entered into, the same shall contain
indemnification provisions and procedures customary in underwritten offerings,
and (v) deliver such documents and certificates as may be reasonably requested
by the Holders of a majority of the Registrable Securities being sold in
connection therewith, their counsel and the managing underwriter(s), if any, to
evidence the continued validity of the representations and warranties made
pursuant to clause (i) above and to evidence compliance with any customary
conditions contained in the underwriting agreement or other agreement entered
into by the Company.


    
      
         


      

      
        -41-

        
          

        

      

      
         


      

    

     

    (11)           Make
available for inspection by a representative of Holders that are selling
stockholders, the managing underwriter(s), if any, and any attorneys or
accountants retained by such Holders or managing underwriter(s), at the offices
where normally kept, during reasonable business hours, financial and other
records, pertinent corporate documents and properties of the Company, and cause
the officers, directors and employees of the Company to supply all information
in each case reasonably requested (and of the type customarily provided in
connection with due diligence conducted in connection with a registered public
offering of securities) by any such representative, managing underwriter(s),
attorney or accountant in connection with such Shelf Registration
Statement.

     

    (12)           Cause
all such Registrable Securities to be listed on each securities exchange on
which similar securities issued by the Company are then listed or, if no similar
securities issued by the Company are then listed on any securities exchange, use
its reasonable best efforts to cause all such Registrable Securities to be
listed on the New York Stock Exchange or NASDAQ, as determined by the
Company.

     

    (13)           If
requested by Holders of a majority of the Registrable Securities being
registered and/or sold in connection therewith, or the managing underwriter(s),
if any, promptly include in a prospectus supplement or amendment such
information as the Holders of a majority of the Registrable Securities being
registered and/or sold in connection therewith or managing underwriter(s), if
any, may reasonably request in order to permit the intended method of
distribution of such securities and make all required filings of such prospectus
supplement or such amendment as soon as practicable after the Company has
received such request.

     

    (14)           Timely
provide to its security holders earning statements satisfying the provisions of
Section 11(a) of
the Securities Act and Rule 158 thereunder.

     

    (d)           Suspension of
Sales.  During any Scheduled Black-out Period and upon receipt
of written notice from the Company that a registration statement, prospectus or
prospectus supplement contains or may contain an untrue statement of a material
fact or omits or may omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading or that circumstances
exist that make inadvisable use of such registration statement, prospectus or
prospectus supplement, each Holder of Registrable Securities shall forthwith
discontinue disposition of Registrable Securities until termination of such
Scheduled Black-out Period or until such Holder has received copies of a
supplemented or amended prospectus or prospectus supplement, or until such
Holder is advised in writing by the Company that the use of the
prospectus.  The total number of days that any such suspension may be
in effect in any 180-day period shall not exceed 30 days.

     

    (e)           Termination of Registration
Rights.  A Holder’s registration rights as to any securities
held by such Holder (and its Affiliates, partners, members and former members)
shall not be available unless such securities are Registrable
Securities.


    
      
         


      

      
        -42-

        
          

        

      

      
         


      

    

     

    (f)           Free Writing
Prospectuses.  The Investor shall not use any free writing
prospectus (as defined in Rule 405) in connection with the sale of Registrable
Securities without the prior written consent of the Company.

     

    (g)           Indemnification.

     

    (1)           The
Company agrees to indemnify each Holder and, if a Holder is a person other than
an individual, such Holder’s officers, directors, employees, agents,
representatives and Affiliates, and each person, if any, that controls a Holder
within the meaning of the Securities Act (each, an “Indemnitee”), against any and
all Losses, joint or several, arising out of or based upon any untrue statement
or alleged untrue statement of material fact contained in any registration
statement, including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto or any documents incorporated
therein by reference or contained in any free writing prospectus (as such term
is defined in Rule 405) prepared by the Company or authorized by it in writing
for use by such Holder (or any amendment or supplement thereto); or any omission
to state therein a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under which they were
made, not misleading; provided, that the Company
shall not be liable to such Indemnitee in any such case to the extent that any
such loss, claim, damage, liability (or action or proceeding in respect thereof)
or expense arises out of or is based upon (i) an untrue statement or omission
made in such registration statement, including any such preliminary prospectus
or final prospectus contained therein or any such amendments or supplements
thereto or contained in any free writing prospectus (as such term is defined in
Rule 405) prepared by the Company or authorized by it in writing for use by such
Holder (or any amendment or supplement thereto), in reliance upon and in
conformity with information regarding such Indemnitee or its plan of
distribution or ownership interests which was furnished in writing to the
Company by such Indemnitee for use in connection with such registration
statement, including any such preliminary prospectus or final prospectus
contained therein or any such amendments or supplements thereto, or
(ii)  offers or sales effected by or on behalf such Indemnitee “by
means of” (as defined in Rule 159A) a “free writing prospectus” (as defined in
Rule 405) that was not authorized in writing by the Company.

     

    (2)           If
the indemnification provided for in Section 4.7(g)(1) is
unavailable to an Indemnitee with respect to any Losses or is insufficient to
hold the Indemnitee harmless as contemplated therein, then the Company, in lieu
of indemnifying such Indemnitee, shall contribute to the amount paid or payable
by such Indemnitee as a result of such Losses in such proportion as is
appropriate to reflect the relative fault of the Indemnitee, on the one hand,
and the Company, on the other hand, in connection with the statements or
omissions which resulted in such Losses as well as any other relevant equitable
considerations.  The relative fault of the Company, on the one hand,
and of the Indemnitee, on the other hand, shall be determined by reference to,
among other factors, whether the untrue statement of a material fact or omission
to state a material fact relates to information supplied by the Company or by
the Indemnitee and the parties’ relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission;
the Company and each Holder agree that it would not be just and equitable if
contribution pursuant to this Section 4.7(g)(2) were
determined by pro rata
allocation or by any other method of allocation that does not take account of
the equitable considerations referred to in Section 4.7(g)(1).  No
Indemnitee guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of
the Securities Act) shall be entitled to contribution from the Company if the
Company was not guilty of such fraudulent misrepresentation.


    
      
         


      

      
        -43-

        
          

        

      

      
         


      

    

     

    (h)           Assignment of Registration
Rights.  The rights of the Investor to registration of
Registrable Securities pursuant to Section 4.7 may be assigned by
the Investor to a transferee or assignee of Registrable Securities to which
there is transferred to such transferee no less than $1,000,000 in Registrable
Securities; provided,
however, that the
transferor shall, within ten days after such transfer, furnish to the Company
written notice of the name and address of such transferee or assignee and the
number and type of Registrable Securities that are being assigned.

     

    (i)           Holdback.  With
respect to any underwritten offering of Registrable Securities by the Investor
or other Holders pursuant to Section 4.7, the Company agrees
not to effect (other than pursuant to such registration or pursuant to a Special
Registration) any public sale or distribution, or to file any Shelf Registration
Statement (other than such registration or a Special Registration) covering any
of its equity securities, or any securities convertible into or exchangeable or
exercisable for such securities, during the period not to exceed 30 days prior
and 90 days following the effective date of such offering or such longer period
up to 180 days as may be requested by the managing underwriter.  The
Company also agrees to cause each of its directors and senior executive officers
to execute and deliver customary lockup agreements in such form and for such
time period up to 180 days as may be requested by the managing
underwriter.

     

    (j)           Rule 144; Rule 144A
Reporting.  With a view to making available to the Investor and
Holders the benefits of certain rules and regulations of the SEC which may
permit the sale of the Registrable Securities to the public without
registration, the Company agrees to:

     

    (1)           make
and keep public information available, as those terms are understood and defined
in Rule 144(c)(1) or any similar or analogous rule promulgated under the
Securities Act, at all times after the effective date of this
Agreement;

     

    (2)           file
with the SEC, in a timely manner, all reports and other documents required of
the Company under the Exchange Act, and if at any time the Company is not
required to file such reports, make available, upon the request of any Holder,
such information necessary to permit sales pursuant to Rule 144A (including the
information required by Rule 144A(d)(4) and the Securities Act);

     

    (3)           so
long as the Investor or a Holder owns any Registrable Securities, furnish to the
Investor or such Holder forthwith upon request: a written statement by the
Company as to its compliance with the reporting requirements of Rule 144 under
the Securities Act, and of the Exchange Act; a copy of the most recent annual or
quarterly report of the Company; and such other reports and documents as the
Investor or Holder may reasonably request in availing itself of any rule or
regulation of the SEC allowing it to sell any such securities without
registration; and


    
      
         


      

      
        -44-

        
          

        

      

      
         


      

    

     

    (4)           take
such further action as any Holder may reasonably request, all to the extent
required from time to time to enable such Holder to sell Registrable Securities
without registration under the Securities Act.

     

    (k)           As
used in this Section 4.7, the following
terms shall have the following respective meanings:

     

    (1)           “Holder” means the Investor,
any other holder of Registrable Securities to whom the registration rights
conferred by this Agreement have been transferred in compliance with
Section 4.7(h)
hereof, Two-Forty, GRAT and CLAT.

     

    (2)           “Holders’ Counsel” means one
counsel for the selling Holders chosen by Holders holding a majority interest in
the Registrable Securities being registered.

     

    (3)           “Register,” “registered,” and “registration” shall refer to
a registration effected by preparing and (a) filing a registration statement in
compliance with the Securities Act and applicable rules and regulations
thereunder, and the declaration or ordering of effectiveness of such
registration statement or (b) filing a prospectus and/or prospectus supplement
in respect of an appropriate effective registration statement on Form S-3 or
other form approved by the holders of a majority of Registrable Securities
available for sales of securities pursuant to Rule 415 under the Securities
Act.

     

    (4)           “Registrable Securities” means
(A) all Common Stock held by the Investor from time to time and
(B) any equity securities issued or issuable directly or indirectly with
respect to the securities referred to in the foregoing clause (A) by way of
conversion, exercise or exchange thereof or stock dividend or stock split or in
connection with a combination of shares, recapitalization, reclassification,
merger, amalgamation, arrangement, consolidation or other reorganization, provided that, once issued,
such securities will not be Registrable Securities when (i) they are sold
pursuant to an effective registration statement under the Securities Act,
(ii) they shall have ceased to be outstanding; (iii) with respect to any
transferee of the Common Stock who is not an Affiliate of the Investor or a
Holder, they shall be freely transferable pursuant to Rule 144 under the
Securities Act in the hands of such transferee without any volume, holding
period or other limitations; or (iv) they have been sold in a private
transaction in which the transferor’s rights under this Agreement are not
assigned to the transferee of the securities.  No Registrable
Securities may be registered under more than one registration statement at one
time.


    
      
         


      

      
        -45-

        
          

        

      

      
         


      

    


    (5)           “Registration Expenses” means
all expenses incurred by the Company in effecting any registration pursuant to
this Agreement (whether or not any registration or prospectus becomes effective
or final) or otherwise complying with its obligations under this Section 4.7, including, without
limitation, all registration, filing and listing fees (including filings made
with the Financial Industry Regulatory Authority), printing expenses (including
printing of prospectuses and certificates for the Securities), the Company’s
expenses for messenger and delivery services and telephone, fees and
disbursements of counsel for the Company, blue sky fees and expenses, expenses
incurred by the Company in connection with any “road show,” the fees and
disbursements of Holders’ Counsel, and expenses of the Company’s independent
accountants in connection with any regular or special reviews or audits incident
to or required by any such registration, but shall not include Selling Expenses
and the compensation of regular employees of the Company, which shall be paid in
any event by the Company.

     

    (6)           “Rule 144,” “Rule 144A,” “Rule 158,” “Rule 159A,” “Rule 405” and “Rule 415” mean, in each case,
such rule promulgated under the Securities Act (or any successor provision), as
the same shall be amended from time to time.

     

    (7)           “Scheduled Black-out Period”
means the period from and including the last day of a fiscal quarter of the
Company to and including the business day after the day on which the Company
publicly releases its earnings for such fiscal quarter.

     

    (8)           “Selling Expenses” means all
discounts, selling commissions and stock transfer taxes applicable to the sale
of Registrable Securities and fees and disbursements of counsel for any Holder
(other than the fees and disbursements of Holders’ Counsel included in
Registration Expenses), other than $25,000 of fees and disbursements of Holders’
Counsel, which shall be reimbursed by the Company pursuant to Section
4.7(b).

     

    (l)           At
any time, any holder of Securities (including any Holder) may elect to forfeit
its rights set forth in this Section 4.7 from that date
forward; provided, that
a Holder forfeiting such rights shall nonetheless be entitled to participate
under Sections 4.7(a)(4)-(6) in any Pending Underwritten Offering to the
same extent that such Holder would have been entitled to if the holder had not
withdrawn; and provided, further, that no such
forfeiture shall terminate a Holder’s rights or obligations under Section 4.7(f) with respect to
any prior registration or Pending Underwritten Offering.  “Pending Underwritten
Offering” means, with respect to any Holder forfeiting its rights
pursuant to this Section 4.7(l), any
underwritten offering of Registrable Securities in which such Holder has advised
the Company of its intent to register its Registrable Securities either pursuant
to Section 4.7(a)(2) or 4.7(a)(4)
prior to the date of such Holder’s forfeiture.

     

    4.8           Termination of Certain
Sections of the Shareholders Agreement.  The
following sections of the Shareholders Agreement are hereby terminated as of the
Closing: Section 2; Section 3; Section 4; and Section 5.


    
      
         


      

      
        -46-

        
          

        

      

      
         


      

    


    4.9           Market Stand-off Provision.  The
Investor hereby agrees that, until the 90th day
after the Closing (or such lesser time as permitted by the underwriters), the
Investor shall not, without the prior written consent of Keefe, Bruyette &
Woods, Inc. (“Keefe Bruyette”) and the Company, directly or indirectly, (i)
offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant for
the sale of, or otherwise dispose of or transfer any shares of Common Stock or
any securities convertible into or exchangeable or exercisable for Common Stock,
whether now owned, acquired pursuant to this Agreement or hereafter acquired by
the undersigned or with respect to which the undersigned has, acquires pursuant
to this Agreement or hereafter acquires the power of disposition, or file, or
request that the Company file, any registration statement under the Securities
Act, as amended, with respect to any of the foregoing, or (ii) enter into any
swap or any other agreement or any transaction that transfers, in whole or in
part, directly or indirectly, the economic consequence of ownership of Common
Stock, whether any such swap or transaction is to be settled by delivery of
Common Stock or other securities, in cash or otherwise.  In the event
that either (i) during the period that begins on the date that is 15 calendar
days plus three (3) business days before the last day of the 90 day restricted
period and ends on the last day of the 90 day restricted period, the Company
issues an earnings release or material news or a material event relating to the
Company occurs, or (ii) prior to the expiration of the 90 day restricted period,
the Company announces that it will release earnings results during the 16 day
period beginning on the last day of the 90 day restricted period, the
restrictions set forth herein will continue to apply until the expiration of the
date that is 15 calendar days plus three (3) business days after the date on
which the earnings release is issued or the material news or event related to
the Company occurs.  The Company shall promptly notify Keefe Bruyette
of any earnings releases, news or events that may give rise to an extension of
the initial restricted period.  For the avoidance of doubt and
notwithstanding Section 6.12 of this Agreement, Keefe Bruyette shall be an
express third party beneficiary of this Section 4.9.  In the event the
restrictions in this Section 4.9 are waived for any investor in the Other
Private Placements, such restrictions shall be deemed automatically waived for
the Investor.

     

    Notwithstanding
the foregoing, the Investor may transfer Common Stock (i) as a bona fide gift or gifts,
provided that the donee or donees thereof agree to be bound in writing by the
restrictions set forth in this Section 4.9, (ii) to any trust for the direct or
indirect benefit of the Investor or the immediate family of the Investor,
provided that the trustee of the trust agrees to be bound in writing by the
restrictions set forth in this Section 4.9, and provided further that any
such transfer shall not involve a disposition for value, (iii) to any Affiliate
of the Investor, provided that such Affiliate agrees to be bound in writing by
the restrictions set forth in this Section 4.9, (iii) to charitable
organizations exempt from taxation under Section 501(c)(3) of the Internal
revenue Code of 1986; provided that such charitable
organizations agree to be bound in writing by the restrictions set forth in this
Section 4.9 or (iv) by way of testate or intestate succession or by operation of
law.  For purposes of this Section, “immediate family” shall mean any
relationship by blood, marriage or adoption, not more remote than first
cousin.

     

    
      
        
        

      

      
        -47-

        
          

        

      

      
        
        

      

    

     

    4.10           Gross-Up
Rights.


    (a)           Sale of New
Securities.  For so long as the Investor, together with his
Affiliates, owns 5% or more of all of the outstanding shares of Common Stock
(counting for such purposes all shares of Common Stock into or for which any
securities owned by the Investor are directly or indirectly convertible or
exercisable and, for the avoidance of doubt, including as shares owned and
outstanding all Common Shares issued by the Company after the Closing) (before
giving effect to any issuances triggering provisions of this Section), if, at
any time after the date hereof, the Company makes any public or nonpublic
offering or sale of any equity (including Common Stock, preferred stock or
restricted stock), or any securities, options or debt that is convertible or
exchangeable into equity or that includes an equity component (such as, an
“equity kicker”) (including any hybrid security) (any such security, a “New Security”) (other than
(i) any Common Stock or other securities issuable upon the exercise or
conversion of any securities of the Company issued or agreed or contemplated to
be issued as of the date hereof, including the Public Offering; (ii) pursuant to
the granting or exercise of employee stock options or other stock incentives
pursuant to the Company’s stock incentive plans approved by the Board of
Directors or the issuance of stock pursuant to the Company’s employee stock
purchase plan approved by the Board of Directors or similar plan where stock is
being issued or offered to a trust, other entity or otherwise, for the benefit
of any employees, officers or directors of the Company, in each case in the
ordinary course of providing incentive compensation; or (iii) issuances of
capital stock as full or partial consideration for a merger, acquisition, joint
venture, strategic alliance, license agreement or other similar nonfinancing
transaction) at a price per share for such New Security (or conversion or
exchange price per share) that is less than 95% of the Market Price on the last
trading day preceding the date of the agreement with respect to the issuance of
such New Securities, then the Investor shall be afforded the opportunity to
acquire from the Company for the same price (net of any underwriting discounts
or sales commissions) and on the same terms (except that, to the extent
permitted by law and the Articles of Incorporation and bylaws of the Company,
the Investor may elect to receive such securities in nonvoting form, convertible
into voting securities in a widely dispersed or public offering) as such
securities are proposed to be offered to others, up to the amount of New
Securities in the aggregate required to enable him to maintain his proportionate
Common Stock-equivalent interest in the Company immediately prior to any such
issuance of New Securities; provided, that such right to acquire such securities
is not transferrable except to Affiliates of the Investor.  The amount
of New Securities that the Investor shall be entitled to purchase in the
aggregate shall be determined by multiplying (x) the total number or principal
amount of such offered New Securities by (y) a fraction, the numerator of which
is the number of shares of Common Stock held by the Investor, and the
denominator of which is the number of shares of Common Stock then
outstanding.  For the purposes of this Section 4.10, the “Market Price” of the Common
Stock (or other relevant capital stock or equity interest) on any date of
determination means the closing sale price or, if no closing sale price is
reported, the last reported sale price of the shares of the Common Stock (or
other relevant capital stock or equity interest) on NASDAQ on such
date.  If the Common Stock (or other relevant capital stock or equity
interest) is not traded on NASDAQ on any date of determination, the closing
price of the Common Stock (or other relevant capital stock or equity interest)
on such date of determination means the closing sale price as reported in the
composite transactions for the principal U.S. national or regional securities
exchange on which the Common Stock (or other relevant capital stock or equity
interest) is so listed or quoted, or, if no closing sale price is reported, the
last reported sale price on the principal U.S. national or regional securities
exchange on which the Common Stock (or other relevant capital stock or equity
interest) is so listed or quoted, or if the Common Stock (or other relevant
capital stock or equity interest) is not so listed or quoted on a U.S. national
or regional securities exchange, the last quoted bid price for the Common Stock
(or other relevant capital stock or equity interest) in the over-the-counter
market as reported by Pink Sheets LLC or similar organization, or, if that bid
price is not available, the market price of the Common Stock (or other relevant
capital stock or equity interest) on that date as determined by a nationally
recognized independent investment banking firm retained by the Company for this
purpose.


    
      
         


      

      
        -48-

        
          

        

      

      
         


      

    


    (b)           Notice.  In
the event the Company proposes to offer or sell New Securities, it shall give
the Investor written notice of its intention, describing the price (or range of
prices), anticipated amount of securities, timing, and other terms upon which
the Company proposes to offer the same (including, in the case of a registered
public offering and to the extent possible, a copy of the prospectus included in
the registration statement filed with respect to such offering), no later than
two business days, as the case may be, after the initial filing of a
registration statement with the SEC with respect to an underwritten public
offering, after the commencement of marketing with respect to a Rule 144A
offering or after the Company proposes to pursue any other
offering.  The Investor shall have 5 business days from the date of
receipt of such a notice to notify the Company in writing that he intends to
exercise his rights provided in this Section 4.10 and, as to the amount of New
Securities the Investor desires to purchase, up to the maximum amount calculated
pursuant to Section 4.10(a).  Such notice shall constitute a
nonbinding indication of interest of the Investor to purchase the amount of New
Securities so specified at the price and other terms set forth in the Company’s
notice to it.  The failure of the Investor to respond within such 5
business day period shall be deemed to be a waiver of such Investor’s rights
under this Section 4.10 only with respect to the offering described in the
applicable notice.

     

    (c)           Purchase
Mechanism.  If the Investor exercises his rights provided in
this Section 4.10, the closing of the purchase of the New Securities with
respect to which such right has been exercised shall take place within 30
calendar days after the giving of notice of such exercise, which period of time
shall be extended for a maximum of 180 days in order to comply with applicable
laws and regulations (including receipt of any applicable regulatory or
stockholder approvals).  Each of the Company and the Investor agrees
to use commercially reasonable efforts to secure any regulatory or stockholder
approvals or other consents, and to comply with any law or regulation necessary
in connection with the offer, sale and purchase of, such New
Securities.

     

    (d)           Failure of
Purchase.  In the event the Investor fails to exercise his
rights provided in this Section 4.10 within said 5 business day period or, if so
exercised, the Investor is unable to consummate such purchase within the time
period specified in Section 4.10(c) because of his failure to obtain any
required regulatory or stockholder consent or approval, the Company shall
thereafter be entitled (during the period of 60 days following the conclusion of
the applicable period) to sell or enter into an agreement (pursuant to which the
sale of the New Securities covered thereby shall be consummated, if at all,
within 90 days from the date of said agreement) to sell the New Securities not
elected to be purchased pursuant to this Section 4.10 by the Investor or which
the Investor is unable to purchase because of such failure to obtain any such
consent or approval, at a price and upon terms no more favorable in the
aggregate to the purchasers of such securities than were specified in the
Company’s notice to the Investor.  Notwithstanding the foregoing, if
such sale is subject to the receipt of any regulatory or stockholder approval or
consent or the expiration of any waiting period, the time period during which
such sale may be consummated shall be extended until the expiration of five (5)
business days after all such approvals or consents have been obtained or waiting
periods expired, but in no event shall such time period exceed 180 days from the
date of the applicable agreement with respect to such sale.  In the
event the Company has not sold the New Securities or entered into an agreement
to sell the New Securities within said 60-day period (or sold and issued New
Securities in accordance with the foregoing within 90 days from the date of said
agreement (as such period may be extended in the manner described above for a
period not to exceed 180 days from the date of said agreement)), the Company
shall not thereafter offer, issue or sell such New Securities without first
offering such securities to the Investor in the manner provided
above.


    
      
         


      

      
        -49-

        
          

        

      

      
         


      

    

     

    (e)           Non-Cash
Consideration.  In the case of the offering of securities for a
consideration in whole or in part other than cash, including securities acquired
in exchange therefor (other than securities by their terms so exchangeable), the
consideration other than cash shall be deemed to be the fair value thereof as
determined by the Board of Directors; provided, however, that such fair value
as determined by the Board of Directors shall not exceed the aggregate market
price of the securities being offered as of the date the Board of Directors
authorizes the offering of such securities.

     

    (f)           Cooperation.  The
Company and the Investor shall cooperate in good faith to facilitate the
exercise of the Investor’s rights under this Section 4.10, including to secure
any required approvals or consents.

     

    4.11           Anti-Takeover
Matters.

     

    (a)           Takeover Laws; No Rights
Triggered.  If any Takeover Law may become, or may purport to
be, applicable to the transactions contemplated or permitted by this Agreement,
the Company and the members of the Board of Directors shall grant such approvals
and take such actions as are necessary so that the transactions contemplated or
permitted by this Agreement, the other Transaction Documents may be consummated,
as promptly as practicable, on the terms contemplated by this Agreement and the
other respective Transaction Documents, as the case may be, and otherwise act to
eliminate or minimize the effects of any Takeover Law on any of the transactions
contemplated or permitted by this Agreement and the other Transaction
Documents.

     

    (b)           Oregon Business Combination
Statute.  The Board of Directors has duly adopted an
irrevocable resolution as follows (the “Business Combination Exemption
Resolution”):

     

    “RESOLVED,
that pursuant to Section 60.835 of the Oregon Business Corporation Act (“OBCA”),
the Board of Directors of the Corporation, for the specific purpose of
establishing an irrevocable exemption from Section 60.835 of the OBCA, hereby
approves thereunder (i) the entering into, and all of the transactions relating
to and contemplated or permitted by, the Securities Purchase Agreement, between
the Corporation and David F. Bolger, in his individual capacity, including,
without limitation, (A) the assignment of any rights thereunder, (B) any person
or entity becoming an “interested shareholder” as defined in Section 60.825 of
the OBCA including, without limitation, David F. Bolger, the estate of David F.
Bolger, any present or future affiliates or associates of David F. Bolger, any
trust David F. Bolger has or may establish, Thomas M. Wells (whether
individually or in another capacity) and Clarence Jones (collectively, the
“Covered Persons”) and
(C) the transfer of any shares of common stock or other securities of the
Corporation in accordance with the terms and conditions of the Securities
Purchase Agreement, (ii) any transaction in which any Covered Person becomes an
“interested shareholder” as defined in Section 60.825 of the OBCA or acquires
additional shares of common stock or other securities of the Corporation
thereafter and (iii) any “business combination” as defined in Section 60.825 of
the OBCA involving any Covered Person.”


    
      
         


      

      
        -50-

        
          

        

      

      
         


      

    

     

    (c)           Business Combination
Exemption.  The Business Combination Exemption Resolution
adopted by the Company is a valid action of the Board of Directors of the
Company, binding on the Company, and constitutes a valid and irrevocable
exemption by the Company from Section 60.835 of the Oregon Business Corporation
Act as to any transaction, person or entity described in such
resolution.

     

    4.12           Additional Regulatory
Matters.

     

    (a)           Each
of the Company and the Investor agrees to cooperate and use its reasonable best
efforts to ensure, including by communicating with each other with respect to
their respective purchases of Common Stock, that none of the Investor’s
Affiliates will become, or control, a “bank holding company” within the meaning
of the BHC Act and the Change in Bank Control Act of 1978.

     

    (b)           The
Company shall not knowingly take any action which would reasonably be expected
to pose a substantial risk that any of the Investor’s Affiliates will become, or
control, a “bank holding company” within the meaning of the BHC Act, including
undertaking any redemption, recapitalization, or repurchase of Common Stock, of
securities or rights, options, or warrants to purchase Common Stock, or
securities of any type whatsoever that are, or may become, convertible into or
exchangeable into or exercisable for Common Stock in each case, where the
Investor is not given the right to participate in such redemption,
recapitalization, or repurchase to the extent of the Investor’s pro rata
proportion.

     

    (c)           Notwithstanding
anything in this Agreement, in no event will the Investor or any of his
Affiliates be obligated to:

     

    (1)           Without
limiting clause (2) below, (A) propose or accept any divestiture of any of the
Investor’s or any of his Affiliates’ assets, or (B) accept any operational
restriction on the Investor’s or any of his Affiliates’ business, or agree to
take any action that limits the Investor’s or his Affiliates’ commercial
practices in any way (except as they relate to the Company and the Company
Subsidiaries) ) including, without limitation, by requiring the modification of
governance, fee or carried interest arrangements with respect to, or otherwise
by imposing any capital or other requirements on, the Investor or any of its
Affiliates, (C) agree to provide capital to, or otherwise maintain or
contribute, directly or indirectly, to the capital of, the Company or any
Company Subsidiary (including the Company Bank) other than the aggregate amount
of the Purchase Price, or (D) register as a bank holding company, in each case
in order to obtain any consent, acceptance or approval of any Governmental
Entity to consummate the transactions contemplated by this Agreement and the
other Bolger Transaction Document; or

     

    (2)           Propose
or agree to accept any term or condition or otherwise modify the terms of this
Agreement or any other Bolger Transaction Document, including, for the avoidance
of doubt, the terms or the amount of the Securities to be delivered by the
Company under this Agreement, to obtain any consent, acceptance, approval of any
Governmental Entity to the consummation of the transactions contemplated by this
Agreement and the other Bolger Transaction Document if such term, condition,
modification or confirmation would (A) materially adversely affect (with respect
to the Investor or his Affiliates) any material term of the transactions, or (B)
reasonably be expected to adversely affect (with respect to the Investor or his
Affiliates) any material financial term of the transactions contemplated by this
Agreement and the other Bolger Transaction Document or the anticipated benefits
to the Investor and its Affiliates hereunder.


    
      
         


      

      
        -51-

        
          

        

      

      
         


      

    

     

    ARTICLE
V

     

    Termination

     

    5.1           Termination. This
Agreement may be terminated prior to the Closing:

     

    (a)           by
mutual written consent of the Investor and the Company;

     

    (b)           by
the Company, upon written notice to the Investor, in the event that the
conditions of Closing set forth in Section 1.2(c)(2) are not satisfied on or
before December 31, 2009;

     

    (c)           by
the Company or the Investor, upon written notice to the other parties, in the
event that any Governmental Entity shall have issued any order, decree or
injunction or taken any other action restraining, enjoining or prohibiting any
of the transactions contemplated by this Agreement, and such order, decree,
injunction or other action shall have become final and
nonappealable;

     

    (d)           by
the Investor, upon written notice to the Company, in the event that the
conditions of Closing set forth in Section 1.2(c)(1) are not satisfied on or
before December 31, 2009;

     

    (e)           by
the Investor, if the Investor or any of its Affiliates receives notice from or
is otherwise advised by the FDIC that the contribution by the Company to its
principal depository institution Subsidiary contemplated by Section
1.2(c)(1)(vi) would not satisfy the “Leverage Capital Ratio” and other capital
requirements of the FDIC set forth in paragraph 4 of the Order, or comparable
requirements in any other enforcement order issued by a federal or state banking
regulator between the date of this agreement and the Closing; or

     

    (f)           by
the Investor, if a “change in control” within the meaning of any Benefit Plan
occurs on or after the date hereof but prior to the Closing
Date.


    
      
         


      

      
        -52-

        
          

        

      

      
         


      

    

     

    5.2           Effects of
Termination.

     

      In
the event of any termination of this Agreement as provided in Section 5.1,
this Agreement (other than Section 3.2, Section 4.6, this Section 5.2 and
Article VI (other than Section 6.1) and all applicable defined terms, which
shall remain in full force and effect) shall forthwith become wholly void and of
no further force and effect; provided that nothing herein
shall relieve any party from liability for willful breach of this
Agreement.

     

    ARTICLE
VI

     

    Miscellaneous

     

    6.1           Survival.  Each
of the representations and warranties set forth in this Agreement shall survive
the Closing under this Agreement but only for a period of 24 months following
the Closing Date (or until final resolution of any claim or action arising from
the breach of any such representation and warranty, if notice of such breach was
provided prior to the end of such period) and thereafter shall expire and have
no further force and effect; provided that the
representations and warranties in Sections 2.2(a), 2.2(b), 2.2(c), 2.2(d)
and 2.3(a) shall survive indefinitely and the representations and warranties in
Sections 2.2(i),
2.2(p) and 2.2(u) shall survive until 90 days after the expiration of the
applicable statutory periods of limitations.  Except as otherwise
provided herein, all covenants and agreements contained herein shall survive for
the duration of any statutes of limitations applicable thereto or until, by
their respective terms, they are no longer operative.

     

    6.2           Amendment.  No
amendment or waiver of this Agreement will be effective with respect to any
party unless made in writing and signed by an officer of a duly authorized
representative of such party.

     

    6.3           Waivers.  No
failure or delay by any party in exercising any right, power or privilege
hereunder shall operate as a waiver thereof nor shall any single or partial
exercise thereof preclude any other or further exercise thereof or the exercise
of any other right, power or privilege.  The conditions to each
party’s obligation to consummate the Closing are for the sole benefit of such
party and may be waived by such party in whole or in part to the extent
permitted by applicable law.  No waiver of any party to this Agreement
will be effective unless it is in a writing signed by a duly authorized officer
of the waiving party that makes express reference to the provision or provisions
subject to such waiver.

     

    6.4           Counterparts and
Facsimile.  For
the convenience of the parties hereto, this Agreement may be executed in any
number of separate counterparts, each such counterpart being deemed to be an
original instrument, and all such counterparts will together constitute the same
agreement.  Executed signature pages to this Agreement may be
delivered by facsimile and such facsimiles will be deemed as sufficient as if
actual signature pages had been delivered.

     

    6.5           Governing
Law.  This
Agreement will be governed by and construed in accordance with the laws of the
State of New York applicable to contracts made and to be performed entirely
within such State.  The parties hereto irrevocably and unconditionally
agree that any suit or proceeding arising out of or relating to this Agreement
and the transactions contemplated hereby will be tried exclusively in the U.S.
District Court for the Southern District of New York or, if that court does not
have subject matter jurisdiction, in any state court located in The City and
County of New York and the parties agree to submit to the jurisdiction of, and
to venue in, such courts.


    
      
         


      

      
        -53-

        
          

        

      

      
         


      

    

    

      6.6           Waiver of Jury
Trial.  EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES
ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR
RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

       

      6.7           Notices.  Any
notice, request, instruction or other document to be given hereunder by any
party to the other will be in writing and will be deemed to have been duly given
(a) on the date of delivery if delivered personally or by telecopy or facsimile,
upon confirmation of receipt, (b) on the first business day following the date
of dispatch if delivered by a recognized next-day courier service, or (c) on the
third business day following the date of mailing if delivered by registered or
certified mail, return receipt requested, postage prepaid.  All
notices hereunder shall be delivered as set forth below, or pursuant to such
other instructions as may be designated in writing by the party to receive such
notice.

       

      (1)           If
to the Investor:

       

      David F.
Bolger

      c/o
Bolger & Co., Inc.

      79
Chestnut Street

      Ridgewood,
New Jersey 07450

       

      Facsimile:  (201)
670-9685

       

      with a
copy to (which copy alone shall not constitute notice):

       

      Wells,
Jaworski, & Liebman LLP

      12 Route
17 North

      Paramus,
New Jersey 07653

      Attn:  Thomas
M. Wells, Esq.

      Facsimile:  (201)
587-8845

      


      and

      


      Sullivan
& Cromwell LLP

      125 Broad
Street

      New York,
New York  10004

      Attn:  Mark
J. Menting and Robert W. Downes

      Facsimile:  (212)
558-3588


      
        
           


        

        
          -54-

          
            

          

        

        
           


        

      


      (2)           If
to the Company:

       

      Cascade
Bancorp

      1100 N.W.
Wall Street

      Bend,
Oregon  97701

      Attn:  Chief
Executive Officer

      Facsimile:  (541)
617-3149

       

      with
copies to (which copy alone shall not constitute notice):

       

      Davis
Wright Tremaine LLP

      1201
Third Avenue, Suite 2200

      Seattle,
Washington  98101

      Attn:  David
R. Wilson

      Facsimile:  (206)
757-7274

       

      6.8           Entire Agreement;
Assignment.  This Agreement (including the Exhibits, Schedules,
and Disclosure Schedules hereto), the Bolger Transaction Document, the
Shareholders Agreement and the Agreement of Merger, dated as of
December 27, 2005, by and among F&M Holding Company, the Company, Igloo
Acquisition Corporation and the Investor constitute the entire agreement, and
supersede all other prior agreements, understandings, representations and
warranties, both written and oral, between the parties, with respect to the
subject matter hereof; neither this Agreement nor the rights and obligations
hereunder may be assigned, sold, transferred, delegated, or otherwise disposed
of by any party hereto except (i) with the express prior written consent of the
other party or (ii) upon the Investor’s death, the rights and obligations of the
Investor under this Agreement shall be assigned to the Investor’s estate or to a
successor-in-interest by operation of law without any further act, including to
his heirs.  Any purported assignment, transfer or delegation in
violation of this Section 6.8 shall be null and void.  Except as
otherwise provided in this Section 6.8, the terms and conditions of this
Agreement shall inure to the benefit of and be binding on the respective heirs,
successors, devisees and assigns of the parties.  For the avoidance of
doubt, the Company agrees that the Investor may assign his rights and
obligations under this Agreement to any Affiliate and any such transferee shall
be included in the term “Investor”.

       

      6.9           Other
Definitions.  Wherever required by the context of this
Agreement, the singular shall include the plural and vice versa, and the
masculine gender shall include the feminine and neuter genders and vice versa,
and references to any agreement, document or instrument shall be deemed to refer
to such agreement, document or instrument as amended, supplemented or modified
from time to time.  All article, section, paragraph or clause
references not attributed to a particular document shall be references to such
parts of this Agreement, and all exhibit, annex and schedule references not
attributed to a particular document shall be references to such exhibits,
annexes and schedules to this Agreement.  When used
herein:

       

      (1)           the
term “subsidiary” means
those corporations, banks, savings banks, associations and other persons of
which such person owns or controls 25% or more of the outstanding equity
securities either directly or indirectly through an unbroken chain of entities
as to each of which 25% or more of the outstanding equity securities is owned
directly or indirectly by its parent or otherwise controlled by such parent and
any entity that would be a “subsidiary” for purposes of the BHC Act; provided, however, that there shall not
be included any such entity to the extent that the equity securities of such
entity were acquired in satisfaction of a debt previously contracted in good
faith or are owned or controlled in a bona fide fiduciary
capacity;


      
        
           


        

        
          -55-

          
            

          

        

        
           


        

      


      (2)           the
term “Affiliate” means,
with respect to any person, any person directly or indirectly controlling,
controlled by or under common control with, such other person.  For
purposes of this definition, “control” (including, with
correlative meanings, the terms “controlled by” and “under common control with”)
when used with respect to any person, means the possession, directly or
indirectly, of the power to cause the direction of management and/or policies of
such person, whether through the ownership of voting securities by contract or
otherwise and “controlled” for purposes of the BHC Act;

       

      (3)           the
word “or” is not exclusive;

       

      (4)           the
words “including,” “includes,” “included” and “include” are deemed to be
followed by the words “without
limitation”;

       

      (5)           the
terms “herein,” “hereof” and “hereunder” and other words of
similar import refer to this Agreement as a whole and not to any particular
section, paragraph or subdivision;

       

      (6)           the
words “it” or “its” are deemed to mean
“him” or “her” and “his” or “her”, as applicable, when
referring to an individual;

       

      (7)           “business day” means any day
except Saturday, Sunday and any day which shall be a legal holiday or a day on
which banking institutions in the State of New York or the State of Oregon
generally are authorized or required by law or other governmental actions to
close;

       

      (8)           “person” has the meaning given
to it in Section 3(a)(9) of the Exchange
Act and as used in Sections 13(d)(3) and 14(d)(2) of the Exchange
Act;

       

      (9)           “Beneficially Own,” “Beneficial Owner” and “Beneficial Ownership” are
defined in Rules 13d-3 and 13d-5 of the Exchange Act; and

       

      (10)         “knowledge of the Company” or
“Company’s knowledge”
means the actual knowledge after due inquiry of the executive officers of the
Company.

       

      6.10         Captions.  The
article, section, paragraph and clause captions herein are for convenience of
reference only, do not constitute part of this Agreement and will not be deemed
to limit or otherwise affect any of the provisions hereof.


      
        
           


        

        
          -56-

          
            

          

        

        
           


        

      


      6.11         Severability.  If
any provision of this Agreement or the application thereof to any person
(including the officers and directors of the Investor and the Company) or
circumstance is determined by a court of competent jurisdiction to be invalid,
void or unenforceable, the remaining provisions hereof, or the application of
such provision to persons or circumstances other than those as to which it has
been held invalid or unenforceable, will remain in full force and effect and
shall in no way be affected, impaired or invalidated thereby, so long as the
economic or legal substance of the transactions contemplated hereby is not
affected in any manner materially adverse to any party.  Upon such
determination, the parties shall negotiate in good faith in an effort to agree
upon a suitable and equitable substitute provision to effect the original intent
of the parties.

       

      6.12         No Third-Party
Beneficiaries.  Nothing contained in this Agreement, expressed
or implied, is intended to confer or shall confer upon any person other than the
express parties hereto, any benefit right or remedies, except that the
provisions of Sections 3.4, 4.3, 4.6, 4.7 and 4.9 shall inure to the benefit of
the persons referred to in those Sections, including any Holders.  The
representations and warranties set forth in Article II and the covenants set
forth in Articles III and IV have been made solely for the benefit of the
parties to this Agreement and (a) may be intended not as statements of fact, but
rather as a way of allocating the risk to one of the parties if those statements
prove to be inaccurate; (b) have been qualified by reference to the Disclosure
Schedules of each party, each of which contains certain disclosures that are not
reflected in the text of this Agreement; and (c) may apply standards of
materiality in a way that is different from what may be viewed as material by
shareholders of, or other investors in, the Company.

       

      6.13         Time of
Essence.  Time is of the essence in the performance of each and
every term of this Agreement.

       

      6.14         Public
Announcements.  Subject to each party’s disclosure obligations
imposed by law or regulation, each of the parties hereto will cooperate with
each other in the development and distribution of all news releases and other
public information disclosures with respect to this Agreement and any of the
transactions contemplated by this Agreement or the other Transaction Documents,
and no party hereto will make any such news release or public disclosure without
first consulting with the other party hereto and receiving its consent (which
shall not be unreasonably withheld, conditioned, or delayed), and each party
shall coordinate with the other with respect to any such news release or public
disclosure.

       

      6.15         Specific
Performance.  The parties agree that irreparable damage would
occur in the event that any of the provisions of this Agreement were not
performed in accordance with their specific terms.  It is accordingly
agreed that the parties shall be entitled to seek specific performance of the
terms hereof, this being in addition to any other remedies to which they are
entitled at law or equity.

       

      6.16         No
Obligation.  It is understood and agreed that unless and until
there is a definitive executed Agreement among the parties with respect to the
transactions contemplated herein, no party shall be under any legal obligation
of any kind hereunder with respect to such transactions or otherwise, and by
virtue of any written or oral expressions by the parties’ respective
representatives.

       

      *  *  *


      
        
           


        

        
          -57-

          
            

          

        

        
           


        

      


      IN WITNESS WHEREOF, this
Agreement has been duly executed and delivered by the duly authorized officers
of the parties hereto as of the date first herein above written.

       

      
        
          
            
              
                
                  
                    	 
      	
                            CASCADE
      BANCORP

                          
	 
      	 
      	 
      
	 
      	
                            By:

                          	/s/
      Patricia L. Moss
	 
      	 
      	Name:
      Patricia
      L. Moss
	 
      	 
      	Title:  
      Chief
      Executive Officer
	 
      	 
      	 
      
	 
      	
                            DAVID
      F. BOLGER

                             

                          
	 
      	

                            /s/
      David F.
Bolger

                          


                  

                

              

            

          

        

      

      


      [Signature
Page to Securities Purchase Agreement]



      
        
           


        

        
          
          

          
            

          

        

        
           


        

      

      


      
        
          
            
              	 
      	
                      TWO-FORTY ASSOCIATES,
      L.P., solely for
      purposes of Sections 3.4, 4.7 and 4.8 of the Agreement

                    
	 
      	 
      	 
      
	 
      	
                      By:

                    	/s/
      David
      F. Bolger
	 
      	 
      	
                      Name:

                    	

                      David
      F. Bolger  

                    
	 
      	 
      	
                      Title:

                    	Trustee


            

          

        

      

      


      
        
          
            
              	 
      	
                      THE DAVID F. BOLGER 2008
      GRANTOR RETAINED ANNUITY TRUST, solely for purposes of Sections
      3.4, 4.7 and 4.8 of the Agreement

                    
	 
      	 
      	 
      
	 
      	
                      By:

                    	/s/
      David
      F. Bolger  
	 
      	 
      	
                      Name:

                    	David
      F. Bolger 
	 
      	 
      	
                      Title:

                    	Trustee


            

          

        

      

      


      
        
          
            
              	 
      	
                      THE DAVID F. BOLGER 2008
      NONGRANTOR CHARITABLE LEAD ANNUITY TRUST, solely for purposes of
      Sections 3.4, 4.7 and 4.8 of the Agreement

                    
	 
      	 
      	 
      
	 
      	
                      By:

                    	Thomas
      M. Wells
	 
      	 
      	
                      Name:

                    	Thomas
      M. Wells  
	 
      	 
      	
                      Title:

                    	Trustee 


            

          

        

      

       

      
        
           


        

        
          -2-

          
            

          

        

        
           


        

      


      EXHIBIT
A:  Form of Opinion of Counsel

       

      October
[●], 2009

       

      


       

      To the
Investors listed on Schedule A

      attached
hereto

       

      Ladies
and Gentlemen:

       

      We have
acted as counsel to Cascade Bancorp, an Oregon corporation (the “Company”), for purposes of
rendering an opinion of counsel in connection with the Company’s issuance on the
date hereof to the Investors listed on Schedule A attached hereto (collectively,
the “Investors” and
each individually, an “Investor”) of [●] shares of
common stock, no par value, of the Company (the “Common Stock”) pursuant to
Securities Purchase Agreements, dated as of October 29, 2009, between the
Company and each Investor (the “Agreements”) (the “Offering”).   This
opinion is being furnished in connection with Closing of the transactions
contemplated by the Agreements.  Capitalized terms used herein which
are not otherwise defined shall have the meanings given to them in the
Agreements.

       

      The law
covered by the opinions expressed herein is limited to Oregon Revised Statute
and the federal laws of the United States of America.

      


      This
opinion letter is to be interpreted in accordance with the Guidelines for the
Preparation of Closing Opinions issued by the Committee on Legal Opinions of the
American Bar Association’s Business Law Section as published in 57 Business
Lawyer 875 (February 2002) and the State on the Role of Customary Practice in
the Preparation and Understanding of Third-Party Legal Opinions published in 63
The Business Lawyer 1277 (August 2008).

       

      
        	
                A.

              	
                Assumptions

              


      

       

      For
purposes of this
opinion letter, we have relied
with your permission on the following assumptions:

       

      
        	
                A-1

              	
                As
      to matters of fact material to the opinions expressed herein, we have
      relied upon the statements or
      certificates of the Company and you pursuant to the Agreements and
      upon certificates and statements of government officials and of officers
      of the Company. In addition, we have examined originals or copies of
      documents, corporate records and other writings that we consider relevant
      for the purposes of this opinion. In such examination, we have assumed
      that the signatures on documents and instruments examined by us are
      authentic, that each is what it purports to be, and that all documents and
      instruments submitted to us as copies or facsimiles conform with the
      originals, which facts we have not independently
  verified.

              


      

       

      
        
           


        

        
          
          

          
            

          

        

        
           


        

      


      
        	
                A-2

              	
                In
      making our examination of documents, we have further assumed that (i) each
      party to such documents (other than the Company in connection with the
      Agreements) had the power, legal competence and capacity to enter into and
      perform all of such party’s obligations thereunder, (ii) each party to
      such documents (other than the Company in connection with the Agreements)
      has duly authorized, executed and delivered such documents, (iii) each of
      such documents is enforceable against and binding upon the parties thereto
      (other than the Company in connection with the Agreements), (iv) there is
      no fact or circumstance relating to you or your business that might
      prevent you from enforcing any of the rights provided for in the
      Agreements, (v) there has not been any mutual mistake of fact or
      misunderstanding, fraud, duress or undue influence, (vi) the conduct of
      the parties to the Agreements has complied with any requirement of good
      faith, fair dealing and conscionability, and (vi) you, and any agent
      acting for you in connection with the transactions contemplated by the
      Agreements, have acted in good faith and without notice of any defense
      against the enforcement of any rights created by the Agreements. We have
      also assumed that there are no extrinsic agreements or understandings
      among the parties to the Agreements that would modify or interpret the
      terms of the Agreements or the respective rights or obligations of the
      parties thereunder.

              


      

       

      
        
          	
                  B.

                	
                  Opinions

                


        

      

       

      Based
upon the foregoing, and subject to the assumptions, exceptions, limitations and
qualifications stated herein, it is our opinion that:

       

      
        	
                B-1

              	
                The
      Company has been duly organized and is validly existing as a corporation
      under the laws of the State of
Oregon.

              


      

       

      
        	
                B-2 

              	
                All
      of the issued shares of capital stock of the Company, including the shares
      of Common Stock issued pursuant to the Agreements, have been duly
      authorized and, when issued
      pursuant to the Agreements upon receipt of the consideration provided for
      therein, will be validly issued, fully paid and
    nonassessable.

              


      

       

      
        	
                B-3

              	
                It
      is not necessary to register the shares of Common Stock issued pursuant to
      the Agreements under the Securities
      Act of 1933 in connection with the offer, sale and delivery of the shares
      of Common Stock by the Company to the Investors in accordance with
      the Agreements. 

              


      

       

      
        	
                B-4

              	
                The
      Company’s authorized equity capitalization is as set forth in Section
      2.2(c) of the Securities Purchase
Agreement.

              


      

       

      
        	
                B-5

              	
                Each
      of the Agreements has been duly
      authorized, executed and delivered by the Company and constitutes the
      legal, valid and binding obligation of the Company enforceable against the
      Company in accordance with its terms.


              


      

       

      
        
           


        

        
          -2-

          
            

          

        

        
           


        

      


      
        	
                B-6

              	
                The
      sale and issuance of the shares of Common Stock will not be subject to any
      preemptive rights, rights of first offer or similar rights of any person
      under (a) the certificate of incorporation of the Company as currently in
      effect (the “Charter”), (b) the
      bylaws of the Company as currently in effect (the “Bylaws”), or (c) any
      Company Significant Agreement.

              


      

       

      
        	
                B-7

              	
                The
      sale and issuance of the Common Stock, in accordance with the Agreements
      and the execution, delivery and performance by the Company of its
      obligations under the Agreements will not violate (a) the Charter, (b) the
      Bylaws, (c) applicable laws of the State of Oregon, (d) applicable federal
      laws of the United States or (e) any Company Significant
      Agreement.

              


      

       

      
        	
                B-8

              	
                No
      consent, approval, authorization or order of, or filing with, any Federal
      or Oregon governmental authority or regulatory body is required to be
      obtained or made by the Company for the consummation by the Company of the
      transactions contemplated by the Agreements, including, without
      limitation, each Other Private Placement and the Public Offering, in
      connection with the offering, issuance and sale of the Common Stock,
      except for the filing of a Form D pursuant to federal and applicable state
      blue sky laws and such as have been
obtained.

              


      

       

      
        	
                B-9

              	
                The
      only vote of the stockholders of the Company required to approve (i) the
      amendment of the Articles of Incorporation to increase the number of
      authorized shares of Common Stock to at least such number as shall be
      sufficient to permit the issuance of Common Stock contemplated in the
      Agreements, the issuance of Common Stock in connection with the Other
      Private Placements and the issuance of Common Stock in connection with the
      Public Offering is that more votes are  cast for such proposal
      than are cast against such proposal and (ii) the issuance of such
      authorized shares of Common Stock for purposes of rule 5635 of NASDAQ’s
      listing rules is a majority of the votes cast on such
      proposal.

              


      

       

      
        	
                C.

              	
                Qualifications

              


      

       

      
        	
                C-1

              	
                In
      giving our opinion in B-1 with respect to the valid existence of the
      Company, we are relying solely and without independent investigation on
      our review and examination of the certificate of the Secretary of State of
      the State of Oregon.

              


      

       

      
        	
                C-2

              	
                Insofar as
      performance by the Company of its obligations under the Agreements is
      concerned, we express no opinion as to bankruptcy, insolvency, fraudulent
      transfer, reorganization, moratorium and similar laws of general
      applicability relating to or affecting creditors' rights and to general
      equitable principles, whether considered in proceedings at law or
      equity.

              


      

       

      
        	
                D.

              	
                Exclusions

              


      

       

      In
addition to the foregoing, the opinions expressed above are specifically subject
to the following exclusions:


      
        
           


        

        
          -3-

          
            

          

        

        
           


        

      

       

      
        	
                D-1

              	
                We
      have assumed, and express no opinion with respect to, (a) the correctness,
      accuracy and completeness of representations and warranties made by you
      and set forth in the Agreements or otherwise made, orally or in writing,
      in connection with the offering of the Common Stock and (b) the validity
      of any wire transfers, drafts or checks tendered by
  you.

              


      

       

      
        	
                D-2

              	
                We
      express no opinion as to whether the members of the Company’s Board of
      Directors have complied with their fiduciary duties in connection with the
      authorization and performance of the
Agreements.

              


      

       

      


       

      The
opinions set forth in Part B may be relied upon by you only in connection with
the Agreements and the transactions described therein, and may not be used or
relied upon by you for any other purpose or by any other person for any purpose
whatsoever without, in each instance, our prior written consent.

       

      This
letter speaks as of the time of its delivery on the date set forth herein. We
undertake no obligation to advise you as to subsequent occurrences or
discoveries.

      


      Very
truly yours,

       

       

      


      Davis
Wright Tremaine LLP


      
        
           


        

        
          -4-

          
            

          

        

        
           


        

      

      


      EXHIBIT
B:  Form of Disclosure Letter of Counsel

       

      Although
we have not undertaken to determine independently and do not assume any
responsibility for the accuracy, completeness or fairness of any of the
statements made in the Registration Statement, the Time of Sale Prospectus, or
the Prospectus, and the documents incorporated by reference therein, and any
further amendments or supplements thereto, as applicable, except to the extent
set forth in Paragraph [  ] and Paragraph [  ], we have
reviewed the Registration Statement, the Time of Sale Prospectus, and the
Prospectus, certain corporate and other records and documents furnished to us by
the Company, as well as the documents delivered to you at the Closing, and
participated in conferences with representatives of the Company, their
accountants, you and your counsel at which the contents of the Registration
Statement, the Time of Sale Prospectus, and the Prospectus and related matters
were discussed and reviewed.  On the basis of the information that was
developed in the course of the performance of the services referred to above, we
advise you that nothing has come to our attention that has caused us to believe
that (i) the documents incorporated by reference in the Prospectus relating to
the Offered Shares or any further amendment or supplement thereto made by the
Company prior to the Applicable Time, when such documents became effective or
were so filed under the Exchange Act contained an untrue statement of a material
fact or omitted to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made
when such documents were so filed, not misleading, (ii) any part of the
Registration Statement, when such part became effective, contained an untrue
statement of a material fact or omitted to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, (iii)
the Time of Sale Prospectus, as of the Applicable Time and as of the Closing
Date, contained any untrue statement of a material fact or omitted to state any
material fact necessary in order to make the statements therein, in the light of
circumstances under which they were made, not misleading, or (iv) as of its
date, as of the Applicable Time and as of the Closing Date, the Prospectus
contained or contains an untrue statement of a material fact or omitted or omits
to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading.  We
further advise you that we have no knowledge of any amendment to the
Registration Statement required to be filed or of any contracts or other
documents of a character required to be filed as an exhibit to the Registration
Statement or required to be incorporated by reference into the Prospectus or
required to be described in the Registration Statement, the Base Prospectus or
the Prospectus which are not filed or incorporated by reference or described as
required.


      
        
           


        

        
          
          

          
            

          

        

        
           


        

      


      EXHIBIT
C:  Form of Officer’s Certificate from the Company

       

      OFFICER’S
CERTIFICATE

       

      [●],
2009

      


      The
undersigned, the Chief Executive Officer of Cascade Coast Bancorp, an Oregon
corporation (the “Company”), pursuant to
Section 1.2(c)(1)(xii) of the Securities Purchase Agreement, dated as of October
29, 2009 (the “Agreement”) between the
Company and David F. Bolger, in his individual capacity (the “Investor”), hereby certifies
to the Investor that:

       

      1.           The
Company has performed all obligations required to be performed by it at or prior
to or contemporaneously with the Closing under the Agreement.

       

      2.           The
representations and warranties of the Company set forth in Section 2.2 of the
Agreement were true and correct in all respects as of the date of the Agreement
and are true and correct as of the Closing as though made on and as of the
Closing Date (except to the extent such representations and warranties are made
as of a specific date, in which case such representations and warranties were
true and correct in all respects as of such date).

       

      Capitalized
terms used but not defined herein shall have the meanings given to such terms in
the Agreement.

      


      [Signature
Page Follows]

       

       

       

      


      [Company
Officer’s Certificate]


      
        
           


        

        
          
          

          
            

          

        

        
           


        

      


      IN
WITNESS WHEREOF, the undersigned has executed and delivered this certificate
solely in such respective capacity and not in an individual capacity as of this
___ day of __________, 2009.

       

      
        
          
            	
                    By:  

                  	  
      
	 
      	
                    Name:  Patricia
      L. Moss

                  
	 
      	
                    Title:  Chief
      Executive Officer

                  


          

        

      

      


      [Company
Officer’s Certificate]